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ABSTRACT 
 
Background: Breast and Gynecological cancers are a major public health problem. Smoking is a 
lifestyle associated with several chronic diseases including cancer, and is a cause of preventable 
death. Other lifestyles of public health concern like poor dietary habits and lack of exercise, 
predisposes many people to dyslipidemia, hypertension and obesity; which are risk factors for 
metabolic syndrome, and are associated with cancer.  
Objectives: The purpose of this study is to find if those who smoke, and have the metabolic 
syndrome, are more likely to have breast or gynecological cancers, and to find the distribution by 
education, having health insurance, race/ethnicity and socio-economic status. 
  x 
Methods: A case-control study of females aged 20 years and above who participated in the 
United States National Health and Nutrition Examination Survey (NHANES) 2001-2010. 
Results: Adjusting for age, education, race, marriage, country of birth and income to poverty 
ratio, females who have smoked more than hundred cigarettes in life and still smoke; a) have a 
42 percent less chance of having a breast cancer diagnosis (OR 0.58; 95% CI 0.36 – 0.93,           
p-value 0.025), and b) are 2.67 times as likely to  report a cervical cancer diagnosis as females 
who have smoked less than hundred cigarettes in life (OR 2.67; 95% CI 1.72 – 4.13, p-value 
<.0001). The rate of cervical cancer diagnosis is highest among females who live below the 
federal poverty level and among females aged 30 - 39 years. 
Conclusion: Smoking and metabolic syndrome are very important indicators of reproductive 
health and needs further study. Because smoking is associated with increased odds of having 
cervical cancer, smoking cessation interventions should be an integral part of cervical cancer 
prevention programs and these programs should be targeted at younger females as well as 
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ABSTRACT 
Background: Breast and Gynecological cancers are a major public health problem. Smoking is a 
lifestyle associated with several chronic diseases including cancer, and is a cause of preventable 
death. Other lifestyles of public health concern like poor dietary habits and lack of exercise, 
predisposes many people to dyslipidemia, hypertension and obesity; which are risk factors for 
metabolic syndrome, and are associated with cancer.  
Objectives: The purpose of this study is to find if those who smoke, and have the metabolic 
syndrome, are more likely to have breast or gynecological cancers, and to find the distribution by 
education, having health insurance, race/ethnicity and socio-economic status. 
Methods: A case-control study of females aged 20 years and above who participated in the 
United States National Health and Nutrition Examination Survey (NHANES) 2001-2010. 
Results: Adjusting for age, education, race, marriage, country of birth and income to poverty 
ratio, females who have smoked more than hundred cigarettes in life and still smoke; a) have a 
42 percent less chance of having a breast cancer diagnosis (OR 0.58; 95% CI 0.36 – 0.93, p-
value 0.025), and b) are 2.67 times as likely to  report a cervical cancer diagnosis as females who 
have smoked less than hundred cigarettes in life (OR 2.67; 95% CI 1.72 – 4.13, p-value <.0001).. 
The rate of cervical cancer diagnosis is highest among females who live below the federal 
poverty level and among females aged 30 - 39 years. 
Conclusion: Smoking and metabolic syndrome are very important indicators of reproductive 
health and needs further study. Because smoking is associated with increased odds of having 
cervical cancer, smoking cessation interventions should be an integral part of cervical cancer 
prevention programs and these programs should be targeted at younger females as well as 
females who live below the federal poverty level. 
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Key words/Abbreviations: 
BP Blood Pressure 
BCEO Breast, Cervical, Endometrial and Ovarian 
BC Breast Cancer 
CC Cervical Cancer 
EC Endometrial Cancer 
GC Gynecological Cancer 
HDL High Density Lipoprotein  
MetS Metabolic Syndrome 
NHANES National Health And Nutrition Examination Survey 
OR Odds Ratio 
OC Ovarian Cancer 
 
Caveat: The terms reported cancers and have cancers are used interchangeably only for purposes 
of emphasis from time to time that, this study uses reported cancer cases. The term valid 
respondent is used for study participants who gave answers to questions provided; those who did 
not give answers at all or answered “don’t know” are excluded. The term relevant 
female/participant is used in cases where results of examinations are available. Gynecological 
cancer in this study refers to the three common gynecological cancers (cervical, endometrial and 
ovarian). Nonsmokers in this study include ever smokers who have smoked less than 100 
cigarettes in life.  
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INTRODUCTION 
The epidemiologic transition of the causes of morbidity and mortality is from infections to 
chronic diseases because of lifestyle changes like poor dietary habits including consumption of 
high-fat foods (Omran 2001). The prevalence of chronic diseases is increasing and adding to the 
global disease burden already posed by infections (WMA, 2011). Chronic diseases alone account 
for almost 60% of  all deaths in the world: dominant among the causes is heart disease and 
cancer (Sami M. 2010). Cancer is a very important public health concern globally and  a major 
public health concern in the United States and several other countries, with about 7.6 million 
people dying each year in the world from cancer; cancer accounts for about 13% of all deaths 
worldwide (Siegel, Ward et al. 2011). Almost 24% of all deaths in the world are due to a 
cardiovascular disease and about 19% of all deaths in the world are due to infectious and 
parasitic diseases (lower respiratory infections (7.1%), diarrheal diseases (3.7%), HIV/AIDS 
(3.5%), tuberculosis (2.5%) and malaria (1.5%) (Dal-Ré 2011); cancer ranks second (13% vs. 
24%) as the cause of deaths worldwide after cardiovascular disease and ranks second as the 
cause of death worldwide after infectious diseases (13% vs. 19%). It is noteworthy that each 
year, more people die from cancer globally than from HIV/AIDS, tuberculosis and malaria 
combined; as many as 12.7 million people were diagnosed with some kind of cancer in the year 
2008 (Ferlay, Shin et al. 2010). In the United States of America, cancer ranks second after heart 
disease as the cause of deaths; being responsible for the death of 568,668 Americans in 2009 
(Kochanek K.D et. al. 2011). 
       Cancers of the female reproductive organs are called gynecological cancers (GCs); the five 
major cancers that make up gynecological cancers are cervical, ovarian, endometrial, vaginal and 
vulvar cancers. Vulvar and vaginal cancers are rare, particularly among younger women. 
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Another reproductive tract cancer, found in the fallopian tubes, is quite rare and often is of the 
same cell type as endometrial cancers.  Together these rare cancers constitute 6 – 7% of all GCs. 
Gynecological cancers account for almost 8% of all female tumors. Globally, out of the ten most 
common cancers in females; breast cancer is the first, cervical cancer ranks third, endometrial 
cancer is sixth and ovarian cancer is the seventh in rank (Jemal, Bray et al. 2011). In the year 
2007; 80,976 women in the United States were diagnosed with a gynecologic cancer, and 27,739 
died from a gynecologic cancer.  
        Breast cancer comes second in rank after lung cancer among all cancers: breast cancer 
accounts for as much as 10.9% of all cancers, occurs more commonly among all women 
worldwide with 1.38 million new cases diagnosed in 2008 (Ferlay, Shin et al. 2010). This is 
about 23% of all incident cancer cases. Breast cancer incidence rates (BCIR) are high in most of 
the developed regions of the world compared to the less developed regions of the world apart 
from Japan; BCIR are more than 80 per 100,000 in developed regions and less than 40 per 
100,000 in less developed regions (GLOBOCAN 2008). On the other hand, mortality rates are   
6 – 19 per 100,000 in developed regions  much lower compared to incidence rates and this is due 
to effective intervention programs (screening and treatment) for breast cancer in the developed 
countries resulting in  low overall mortality rates sending breast cancer to 5th place as the overall 
cause of deaths from cancer. Cervical cancer ranks seventh among all cancers and third among 
all cancers in women with 530, 000 incident cases worldwide in 2008 (Ferlay, Shin et al. 2010). 
Low and middle income countries carry the greatest burden about 85%; the European Union 
(EU- 27)   about 5.9%; and the United States of America about 2.1% of the entire burden due to 
cervical cancer incident cases in 2008. Cervical cancer is not part of the top ten cancers in 
females in the United States; cervical cancer ranks 14th among cancers in females (Howlader N 
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et. al 2011). Globally uterine cancer is the most commonly diagnosed gynecological cancer and 
ranks third among cancers affecting females. In the United States, uterine cancer also ranks first 
among gynecological cancers but is the fourth most common cancer in females. The age-adjusted 
death rate for endometrial cancer based on patients who died in 2004-2008 in the United States 
was 4.2 per 100,000 women per year. Ovarian cancer accounts for only about three percent of all 
cancers in females, but is classified the deadliest of all gynecological cancers.  
 
U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2007 Incidence and Mortality Web-based Report. 
Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer 
Institute; 2010. Available at: www.cdc.gov/uscs.Assessed February 14, 2012 
      Five main risk factors associated with cancer are tobacco use, high body mass index, low 
fruit and vegetable intake, lake of physical activity and alcohol use. These risk factors account 
for about 30% of all cancer deaths globally. It is estimated that by the year 2030, the number of 
global cancer deaths will increase from 7.6 million deaths in 2008 to 13.1 million deaths 
(GLOBOCAN, 2008). 
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        Smoking is a major cause of preventable death and disease; the US Surgeon General 
reports that smoking is associated with several chronic diseases including cancer and heart 
disease, and reports the possible mechanisms by which smoking causes these diseases (CDC, 
2010). Globally, tobacco use kills almost six million people yearly.  It is projected that tobacco 
use will kill more than eight million people worldwide if the current trend in tobacco use 
continues; 80% of these premature deaths will be in low and middle income countries. Tobacco 
use is the single most preventable cause of death in the United States; more than 440,000 
premature deaths per year are attributed to tobacco use and this is about one out of every five 
deaths a year. People who smoke loose about 13 – 14 years of their life compared to those who 
do not smoke. In 2010, 21.5% of all adult males and 17.3% of adult females in the United 
States were current smokers and this differed by age, race, education and poverty status with 
about 52% of all current smokers attempting to quit smoking (CDC). People who are more 
educated smoke less than people who are less educated; 45.2% of adults with a GED diploma 
were current smokers, whilst 6.3% of people with a post graduate college degree, 9.9% with 
undergraduate degree, 23.8% with high school diploma, 28.9% of those below the poverty line 
and 18.3% of those who live at or above the poverty line were current smokers in 2010. People 
aged 65 years and older smoke less (9.5%) than people between the ages of 18 years and 64 
years (21% on average). American Indians/Alaskan natives (AI/N) smoke the most ; 31.4% of 
AI/N followed by 21.0% of Whites, 20.0% of Blacks, 12.5% of Hispanics and 9.2% of Asians. 
Whereas there is enough evidence that tobacco causes cancer of the lungs and almost all organs 
in humans, about 25% of people living with cancer still smoke. This is quite unfortunate, 
especially when other people who do not smoke are exposed to second hand smoking putting 
them at risk for cancer as well. 
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        Contemporary demands and changes in lifestyle results in reduced physical activity and 
poor diet which increases the incidence and prevalence of obesity; a major risk factor for several 
chronic diseases including cancer and the metabolic syndrome. Obesity in women has been 
linked to breast cancer and it is important to know if obesity increases the risk of having 
gynecological cancers as well. Metabolic syndrome (MetS) is a combination of metabolic factors 
that increases ones risk of developing cardiovascular diseases, diabetes, stroke or other diseases 
associated with atherosclerosis. The definition of metabolic syndrome includes the basic 
conditions: obesity, insulin resistance, dyslipidemia and hypertension, albeit, different expert 
groups have different clinical criteria for defining metabolic syndrome. Among the most widely 
accepted definitions of metabolic syndrome are those of the World Health Organization (WHO), 
European group for the Study of Insulin Resistance (EGIR) and the National Cholesterol 
Education Program – Third Adult Treatment Panel (NCEP ATP III). The WHO defines MetS as 
impaired glucose tolerance or diabetes with two or more of the following: blood pressure more 
than or equal to 140/90 mmHg, plasma triglycerides of more than or equal to 150mg/dl, lowered 
HDL cholesterol (< 35mg/dl for men or < 39mg/dl for women), waist to hip ratio of > 0.90 for 
men and > 0.85 for women and/or body mass index (BMI) of > 30kg/m2, urinary albumin 
excretion rate of more than or equal to 20 micrograms/min or albumin:creatinine ratio of more 
than or equal to 30mg/g. (WHO 1999). The NCEP ATP III guidelines state that metabolic 
syndrome may be diagnosed in a person who has three or more of the following: central obesity 
(waist circumference of > 102cm for men and >88cm for women), an elevated triglyceride level 
(more than or equal to 150mg/dl), a reduced HDL- cholesterol level(< 40mg/dl for men and 
<50mg/dl for women), high blood pressure of more than or equal to 130/85mmHg, and high 
fasting glucose concentration of more than or equal to 100mg/dl (NCEP ATP III 2001).  
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Metabolic syndrome is quite prevalent among populations and is an increasing problem globally. 
The International Diabetes federation (IDF) identifies the current obesity epidemic as the main 
cause of the high prevalence of MetS. The WHO lists that obesity has more than doubled since 
1980 worldwide; in 2008, about 1.5billion adults 20 years and over were overweight. Out of this 
number, 200 million men and 300 million women were obese. Uterine and breast cancers are 
among the common consequences of being obese. According to the national Health Statistics 
Report about 34% of United States adults aged 20 years and above have the metabolic syndrome, 
the MetS increases with age, its prevalence varies by age and ethnicity and the pattern of MetS 
differs by gender (Ervin, 2009). 
        Breast and gynecological cancers are a major public health problem. Whereas screening 
programs help to reduce the incidence of female cancers through early detection and treatment, 
there is a disparity in access to these services. Screening programs in United States (U.S.)  has 
helped to reduce the incidence and mortality due to cancer, but the U.S. does not provide a basic 
health benefit package to all of its citizens (Sankaranarayanan 2001). Medicare is a health benefit 
program for the elderly above 65 years and the disabled. Medicaid is for people with low income 
in the U.S. Other people must finance their healthcare through various Health Insurance (HI) 
programs/packages (Sigurdsson 2009). Whilst HI premiums are high, it does not pay for all the 
cost of accessing medical service. An insured client still faces co-payments and deductibles when 
he/she gets medical services. People who need healthcare services are not likely to access these 
services because they cannot afford it. A study conducted by Weaver et al concluded that more 
than two million cancer survivors in the US did not get one or more needed medical service 
during the period of 2003 – 2006 because of concern for cost (Weaver, et al., 2010). Evidence 
and information on the relationship between smoking, metabolic syndrome and gynecological 
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cancers as well as their distribution among certain demographic factors such as race/ethnicity, 
education, income and having health insurance can help plan effective intervention programs 
aimed at reducing the burden of gynecological cancers. 
PURPOSE AND HYPOTHESIS 
        The purpose of this study is to find the association and rates of breast and gynecological 
cancers among females who: a) smoke, b) have metabolic syndrome and c) smoke and have 
metabolic syndrome, compared to females who do not have these conditions, and to look at the 
distribution by race/ethnicity, education, socioeconomic status and having health insurance. If 
among females with the above listed risk factors, breast and gynecological cancers are more 
prevalent, then it is likely there is a causal relationship which needs further study to help plan 
programs aimed at reducing the incidence and mortality due to cancers in females. 
        The hypothesis of this study is that in the United States: 
a) Breast and gynecological cancers are more prevalent among females who smoke than 
females who do not smoke. 
b) Breast and gynecological cancers are more prevalent among females who have the 
metabolic syndrome than among females who do not have the metabolic syndrome. 
c) Breast and gynecological cancers are more prevalent among females who smoke and 
have the metabolic syndrome than among females who smoke but do not have the 
metabolic syndrome. 
d) Breast and gynecological cancers are more prevalent among females who smoke and 
have the metabolic syndrome than among females who have the metabolic syndrome and 
do not smoke. 
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LITERATURE REVIEW 
        Antonio Russo et al. conducted a population based study to describe the link between 
metabolic syndrome and cancer risk. The study identified 16,677 records of participants aged 40 
years and over in Milan’s Health Information System from January 01, 1999 to December 31, 
2005, resident in Milan, Italy, who had been concurrently prescribed at least an antihypertensive, 
a hypoglycemic and a hypolipemic with an average follow up period of 2.7 years (Russo, 
Autelitano et al. 2008). Records in the local cancer registry showed that 823 of the participants 
had cancer incident cases during this study period. The number of person years at risk was 
calculated from the index date (date when pharmacological treatment was started) to date of first 
malignant cancer diagnosis or date of death or date of migration or the last date of follow up 
(whichever came first). Standardized Incident Ratios (SIR) and Standardized Mortality Ratios 
(SMR) at 95% confidence intervals under the assumption of a Poisson distribution of observed 
cases were computed as the ratio between observed and expected numbers of site specific 
incident invasive cancer and mortality cases respectively. A significantly increased risk for 
pancreatic cancer in males and colorectal cancer in females was observed, however, they also 
found a non-significant increased risk of liver, gallbladder, biliary tract, breast and endometrial 
cancer among females and concluded that people who had the metabolic syndrome had an 
increased risk of developing several cancers (Russo, Autelitano et al. 2008). The expected 
number of invasive cancers calculated was 302 for females (SIR 104; 95% CI 93–116) and 492 
for males (SIR 103; 95% CI 95–113). Colorectal cancer risk was statistically significant only in 
females (SIR 132; 95% CI 101–170) with a notable increase for rectal cancer sub-site (SIR 180; 
95% CI 112–276). There was a significant increased risk for Pancreatic cancer observed in males 
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(SIR 178; 95% CI 114–266) and females had a similar but not significant risk increase (SIR 145; 
95% CI 87–226). Concerning breast and gynecological cancers, non-significant increased risks 
were observed in females, for breast (SIR 117; 95% CI 95–143) and endometrial cancers (SIR 
156; 95% CI 95–241). Mortality follow up was completed by January 1, 2006. Out of the 1,746 
deaths, 867 deaths were caused by cardiovascular diseases: SMRs were 195 for males (95% CI 
178–213) and 168 for females (95% CI 151–186) and invasive cancers accounted for 345 deaths: 
SMRs were 73 for males (95% CI 64–84) and 81 for females (95% CI 68–95), respectively. 
        Components of the metabolic syndrome have also been studied to assess their association 
with cancer. In the Metabolic syndrome and cancer project (Me-Can) the association between 
serum triglycerides and cancer risk was assessed. Concerning cancers among women, the study 
shows significant increases in the relative risk for total cancer, cervical, respiratory, non-
melanoma skin cancers and other non-specified skin cancers in the top quintile compared to the 
bottom quintile of serum triglycerides (Borena, Stocks et al. 2011). The Metabolic syndrome and 
Cancer project (Me-Can) includes data from population-based cohorts in Norway (The Oslo 
study, the Norwegian Counties study-NCS, the Cohort of Norway-CONOR and the Age 40 
programme-40-y), Austria (the Vorarlberg Health Monitoring and Prevention Programme-
VHM&PP) , and Sweden (The Vasterbotten Intervention Project-VIP and the Malmo Preventive 
Project-MPP) in 2006. Altogether, there were 940 060 subjects and 1 600 296 observations for 
the Me-Can dataset, however, the full Me-Can dataset includes 924,801 participants with 
1,566,553 health examinations after an initial data cleaning process and ultimately data on 
514,097 men and women were used for the serum triglyceride and cancer risk study after 
inclusion criteria were met. Incident cancer cases were identified through linkages with national 
cancer registries of the respective countries and categorized according to the International 
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Classification of Diseases, seventh revision (ICD-7). Taking whichever occurred first; the date of 
the first cancer diagnosis, emigration, death or December 31, 2003 (Austria), 2005 (Norway), 
and 2006 (Sweden), was used as an end-point. Cox proportional hazard regression was used to 
estimate hazard ratios, denoted as relative risks (RR), for triglyceride levels with risk of incident 
cancer. In women, for fasting compared to non-fasting serum triglyceride levels (STG) 
respectively, a significant association for non-melanoma skin cancer of (RR: 4.31; 95% CI, 
1.56–11.9) versus (RR: 0.96; 95% CI, 0.40–2.36) and a borderline significant effect for corpus 
uteri (endometrial) of (RR: 1.74; 95% CI, 0.99–3.09) versus (RR: 1.07; 95% CI, 0.65–1.72) was 
observed and in contrast, only non-fasting STG showed a significant association with cervical 
cancer (RR: 2.64; 95% CI, 1.29–5.52) versus (RR: 1.04; 95% CI, 0.37–2.77). 
        A prospective cohort study examined the association between the metabolic syndrome and 
risk of incident endometrial and fatal uterine corpus cancer among female cohorts in the Me-Can 
study. In all, 287,320 women were enrolled during 1974–2005 and followed for ten years 
calculated as 2.9 million person-years on average (Bjørge, Stocks et al. 2010). A total of 917 
endometrial carcinomas and 129 fatal cancers were identified. The metabolic syndrome was 
assessed as a composite Z score, as the standardized sum of Z scores for body mass index, blood 
pressure, blood/plasma/serum levels of glucose, total cholesterol, and triglycerides. BMI, blood 
pressure, glucose, cholesterol and triglycerides were standardized to Z score variables with mean 
= 0 and standard deviation (SD) = 1. Because data for glucose and triglycerides were skewed and 
had outliers, they were log-transformed before standardization. A score for the metabolic 
syndrome, was calculated by adding the individual Z scores and standardized to a Z score 
variable with mean = 0 and SD = 1. Cox proportional hazards regression models was fitted with 
age as the time variable to calculate relative risks and 95% confidence intervals for endometrial 
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carcinoma incidence and mortality. The models were stratified into six sub-cohorts and adjusted 
for year of birth (up to 1929, 1930–1939, 1940–1949, 1950–1959, and from 1960) and smoking 
status (never, former, and current smokers). Blood pressure, glucose, cholesterol, and 
triglycerides were further adjusted for quintile of body mass index BMI, which is known to be a 
strong risk factor for endometrial cancer. Parity, year(s) of childbirth(s), and physical activity 
were also adjusted for in the Norwegian cohorts, but this did not change the risk estimates by 
much and so these variable were not adjusted for in the final model. Relative risk of endometrial 
carcinoma increased with increasing BMI, blood pressure, glucose level, and triglyceride level. 
There was an increased risk of endometrial carcinoma for the metabolic syndrome (per 1-unit 
increment of Z score, RR = 1.37, 95% CI: 1.28, 1.46. An increased risk was also observed for 
fatal cancer in relation to the metabolic syndrome RR = 1.56, 95% CI: 1.32, 1.84; as well as 
increased risks for all of the individual Z scores except for cholesterol when stratifying for cohort 
and adjusting for year of birth and smoking, and there was increased risk for blood pressure after 
further adjustment for quintile of BMI. 
        The association between MetS and risk of breast cancer incidence and mortality was also 
examined in the Me-Can project. 4,862 incident cases of breast cancer with a mean age of 58 
years at diagnosis and 633 deaths from breast cancer were identified (Bjørge, Lukanova et al. 
2010). Interestingly, women below 50 years of age had a decreased risk of incident breast cancer 
for the MetS (per 1-unit increment of z-score; RR, 0.83; 95% CI, 0.76-0.90) and for the 
individual components examined, except for glucose. Stratifying by age, a decreasing risk of 
breast cancer incidence with increasing BMI (RR 0.70; 95% CI, 0.57-0.85) for the top versus 
bottom quintile was observed in women aged below 50 years. Of the continuous Z-score factors, 
increasing levels of blood pressure, glucose, and the MetS was associated with an increased risk 
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of breast cancer mortality in women above age 60 years. The RR for the MetS was 1.23 (95% 
CI, 1.04-1.45) per 1-unit increment of Z-score with the association for blood pressure and 
glucose being present even after adjustment for the other individual Z-scores. The highest RR 
was observed for glucose (RR, 1.50; 95% CI, 1.05- 2.14). 
         Nagel et al examined the association of metabolic syndrome with rare gynecological 
cancers in the Me-Can project (Nagel, Concin et al. 2011) and found that metabolic syndrome 
was associated with increased risk of vulvar (RR 1.78, 95% CI 1.30 – 2.41) and vaginal cancers 
(RR 1.87, 95% CI 1.07 – 3.35). Increased risk of vulvar cancer was also associated with blood 
glucose (RR 1.98, CI 1.10 – 3.58) and triglyceride levels (RR 2.09, 95% CI 1.39 – 3.15).  
        Experimental studies show that nicotine which is also the active ingredient in tobacco is 
associated with poor cancer prognosis. A randomized control study conducted by Davis et al 
demonstrated that nicotine can promote tumor growth and metastasis in immune-competent mice 
(Davis, Rizwani et al. 2009).  In this study, to assess tumor growth under use of nicotine, mice 
were injected with cultured line-1 mouse adenocarcinoma cells and were randomized to control 
(n=8) and test (n=8) after 3-7 days of the injection. Nicotine was administered to test mice for 
two weeks by intraperitoneal injections at a dose of 1mg/kg three times daily weekly or 
transdermally at a daily dose of 25mg/kg using over the counter nicotine patches, control mice 
were given vehicle with no nicotine. The tumor growth was measured three times weekly. Mice 
that received intraperitoneal nicotine had significantly larger tumors (2267 ± 369 mm3, p-value = 
.019) compared to controls tumors (695 ± 98 mm3, p-value = .002) and for mice that had 
transdermal patch, average tumor volume was 871±106 mm3 compared to controls 530 ± 
59mm3, p-value = 0.002. The tumor was removed and the mice were exposed to nicotine (test) or 
vehicle without nicotine (control) again for 14 days to test for regrowth. There was an average of 
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19  ± 7% tumor recurrence in the control group, as compared to an average of 59 ± 3% tumor 
recurrence in nicotine group (p-value = .01). To test for metastasis, the mice were injected with 
tumor cells, randomized to nicotine 1mg/kg injections (n = 16) or vehicle alone (n = 16) and 
observed for three weeks and tumor removed. The mice received their assigned injections for 
two more weeks. A histological examination of the lung tumors showed that the control group 
had average metastatic foci of 0.9 ± 0.2 compared to 8.1±1.7 in the test group (p-value = .001). 
Surprisingly, metastatic foci for the transdermal patch group was an average of 20.6 ± 4.9 (test 
group) and 6.7 ± 2.1 (control group) p-value = .02. The study concluded that while nicotine has 
limited capacity to initiate tumor formation, nicotine can promote the proliferation and spread of 
cancers which have been caused by other carcinogens in tobacco. 
        A hospital-based case-control study conducted to investigate common and site-specific risk 
factors among gynecologic cancers in females aged 30 years and over admitted to a hospital in 
Miyagi Cancer Center Hospital (MCCH), Miyagi Prefecture, Japan, from 1997 to 2003 
concluded that smoking was significantly associated with an increased risk of cervical cancer 
(Fujita, Tase et al. 2008). Incident cancer cases were identified from a list of the patients linked 
with the hospital-based cancer registry files which records all cancer cases confirmed by clinical, 
cytological and/or histopathological examination at the MCCH; 151 women were diagnosed with 
cervical, 103 with endometrial and 141 with ovarian cancer. 2016 female patients who had no 
history of cancer and did not have cancer were selected as controls. A self-administered 
questionnaire was used to obtain information on reproductive factors, exogenous hormone use, 
and lifestyles including smoking. Odds ratios (ORs) and 95% confidence intervals (95% CIs) for 
active and passive smoking, alcohol intake, marital status, reproductive factor and exogenous 
hormone use were estimated for each cancer site using an unconditional logistic regression 
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model, adjusting for age, year of survey, occupation and other related factors including family 
history of cancer in parents and siblings. Compared with never smokers, active smoking was 
significantly associated with an increased risk of cervical cancer (OR = 2.25, 95% CI, 1.47 – 
3.43).  A significant dose-response relationship was found between the numbers of cigarettes 
smoked per day and the odds of having cervical cancer compared to never smokers: among those 
who smoke less than 10 cigarettes a day (OR= 2.00, 95% CI, 1.12-3.58), among those who 
smoke from 11- 20 cigarettes a day (OR= 2.51, 95% CI, 1.42-4.56), however, among those who 
smoked 20 or more cigarettes a day (OR =1.56, 95% CI, 0.74-3.31) p-value for the trend = 
0.004. A high odds for cervical cancer was also observed (OR = 3.20, CI, 1.22-8.44) in women 
who started smoking before 20 years of age, compared to women who started smoking between 
the age of 20 – 24 years OR = 2.49, CI,1.38-4.51 and those who started smoking after 25 years 
OR =1.94, CI,1.05-3.61. For endometrial cancer, there was a significant decreased risk 
associated with passive smoking (OR = 0.54, CI, 0.32-0.93) and an insignificant decreased risk 
associated with active smoking (OR = 0.54, CI, 0.26-1.13. the odds of having ovarian cancer 
among active smokers was OR =1.04, CI, 0.62-1.72. Alcohol intake was significantly associated 
with a decreased risk of ovarian cancer compared with people who never drank alcohol, OR = 
0.58, CI, 0.35-0.96. 
        Mammographic density (MD) is a strong indicator of breast cancer risk; Lesley Butler et al. 
assessed the associations between active smoking and secondhand smoke (SHS) exposure with 
mammographic density among 799 pre- and early peri-menopausal women who were enrolled in 
the Study of Women’s Health Across the Nation (SWAN). Average percent mammographic 
density, significantly decreased consistently with increased tobacco smoke exposure at a 95% 
confidence interval: Never smoker/no SHS 48.5 (46.3, 50.6), Never smoker/with SHS: 43.1 
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(40.3, 45.8), Former smoker: 40.7 (37.7, 43.6), Current smoker: 38.4 (33.7, 43.0), p-value: 0.001 
(Butler, Gold et al. 2010). Cigarette smoke may exert antiestrogenic effects by influencing 
estrogen metabolism.  Estradiol 2-hydroxylation yields metabolites, such as [2-hydroxyestrone 
(2-OHE)], that have antiestrogenic properties; Lesley Butler et al have previously reported a 
statistically significant trend (p-value 0.0001) of increasing urinary 2-OHE level with increasing 
amount of smoking among pre- and early perimenopausal women in SWAN and as corollary 
concluded that the inverse association observed between smoking and breast density may be due 
to antiestrogenic but not the carcinogenic effects of smoking. Using seven questions adapted 
from the American Thoracic Society and validated self-administered questionnaires, active 
smoke exposure and SHS exposure were assessed at baseline and subsequent follow-up visit. 
The definition for active smoking is not explicitly explained in the study but ever-active smokers 
were defined as having smoked a total of at least 20 packs of cigarettes over one’s lifetime, or at 
least one cigarette per day for at least one year and ever-active smokers who reported no longer 
smoking at the time of interview were classified as former-active smokers. Having SHS exposure 
was defined as at least one total person-hour of SHS exposure during the past seven days. 
Eligible mammograms were those taken as part of routine medical care during the period from 
two years prior to the baseline examination through two years after annual follow-up visit. The 
total area of the breast and the areas of dense breast were measured with a compensating polar 
planimeter (LASICO, Los Angeles, CA) on the craniocaudal view of the right breast or  the left 
breast when films from the right breast were unavailable (n = 81). Percent density was calculated 
by dividing the area of dense breast by the total area of the breast and multiplying by 100. The 
study controlled for age, body mass index (BMI), race/ethnicity, study-site, age at menarche, 
oral-contraceptive use and alcohol consumption in the final model.  
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        The SWAN study also evaluated the association between MetS and mammographic density 
(MD) in 790 enrolled premenopausal and early peri-menopausal women (Conroy, Butler et al. 
2011) and observed a lower mean percent MD for women with the MetS (mean % MD 27.4, SD 
± 17.2) <0.001 and each component of the MetS, compared to those without the metabolic 
abnormality (mean % MD 47.4, SD ± 19.3). The study showed modest inverse associations 
between percent MD and the MetS [β = -2.5, standard error (SE) = 1.9, p = 0.19], abdominal 
adiposity (β = -4.8, SE = 1.9, p = 0.01) and raised glucose (β = -3.7, SE = 2.4, p = 0.12) after 
adjusting for body mass index (BMI) in a cross sectional model; after adjusting for age and BMI 
in longitudinal models, abdominal adiposity (β = 0.34, SE = 0.17, p = 0.05) was significantly 
positively associated with β slower annual decline in percent MD with time. The study 
concluded that, the results do not support the hypothesis that, the MetS increases breast cancer 
risk via a mechanism of increase in percent MD, and gave an explanation that it is possible that 
the effects of abdominal adiposity on breast cancer risk are not mediated by MD but via 
alternative pathways that are not represented by MD. 
        A case-control study to examine the relation between smoking and breast cancer risk in 
non-Hispanic white women under the age of 50 years who carry a deleterious mutation in 
BRCA1 (195 cases and 302 controls) or BRCA2 (128 cases and 179 controls) indicates that 
history of ever smoking is associated with increased risk of breast cancer before age 50 years in 
BRCA1 and BRCA2 mutation carriers (2008). Compared to never smokers, the odds ratios for 
former and current smokers at 95% confidence interval were; OR 1.44 CI: 0.96–2.17 and OR 
2.02 CI: 1.31–3.10 in BRCA1carriers and OR 2.02 CI: 1.37–2.96 and OR 2.35 CI: 1.25–4.43 in 
BRCA2 carriers respectively. Information on selected demographics /lifestyles including 
smoking history, alcohol consumption, oral contraceptive (OC) use, and reproductive and other 
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risk factors were collected using a common structured questionnaire, and information on 
deleterious mutation in either BRCA1 or BRCA2 were ascertained from the Breast Cancer 
Family Registry (Breast CFR). Subjects with a first primary invasive breast cancer were defined 
as cases, and subjects without breast cancer were defined as controls. 
        A case-control study of 272 women attending Obstetrics and Gynecology clinics for 
cervical cytologic screening at the University of Texas Medical Branch in Galveston (UTMB) in 
the US and the Universidad Central in Caracas, Venezuela examined the differential risk 
contribution of sexual behavior and cigarette smoking to cervical cancer (CC) in the U.S. and 
Venezuela (Sierra-Torres, Tyring et al. 2003). The study reported that HPV infection was 
significantly associated with CC in both populations, but compared to US controls, the 
Venezuelan controls were twice as likely to be infected with HPV and that whereas having more 
than two lifetime sexual partners (OR = 4.7, 95% CI = 1.7-13.1) and initiation of sexual 
activities before the age of 18 (OR = 4.7, 95% CI = 1.6-13.7) were significant risk factors in a 
multivariate model for CC in Venezuela, current cigarette smoking was a significant risk factor 
only in the US (OR = 3.6, 95% CI = 1.7-7.7) and not in Venezuela (OR 1.0, 95% C.I. 0.5—2.4). 
Among all the subjects, compared to never smokers, the odds of having CC increased 
significantly in ever smokers ( OR 1.8, 95% C.I  1.1—2.9) and current smokers( OR 2.0 , 95% 
C.I. 1.2—3.5)  as well as pack-years; for ≤ 5years ( OR 1.2 , 95% C.I. 0.7—2.3) and for               
> 15 years (OR 3.9 , 95% C.I 1.6—9.8). The study excluded women who had been exposed to 
chemotherapeutic drugs, had chronic illnesses, or sexually transmitted diseases. Cases consisted 
of 114 women with biopsy-confirmed high-grade cervical intraepithelial neoplasia (HGCIN; i.e., 
CIN 2-3) or invasive CC and controls consisted of 158 women with a history of normal Pap tests 
in the pass than one year or less. Those who reported smoking at the time of study recruitment 
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where classified as current smokers and the number of packs of cigarettes smoked per day 
multiplied by the duration of cigarette smoking in years was calculated as the pack-years, an 
indicator of cumulative smoking dose. 
        A population-based study conducted to assess the risk associated with cigarette smoking, 
with a particular focus on tumor subgroups jointly classified according to the degree of 
invasiveness and histology, identified 812 women aged 35 – 75 years with ovarian cancer 
diagnosed in western Washington State from 2002–2005 through a population-based registry that 
is part of the Surveillance, Epidemiology, and End Results program of the US National Cancer 
Institute (Rossing, Cushing-Haugen et al. 2008). The study selected 1,313 controls with at least 
one ovary and no history of ovarian cancer by random digit dialing using stratified sampling in 
five-year age categories, one year calendar intervals and two county strata in a 2:1 ratio to 
women with invasive epithelial ovarian cancer and assessed the risk associated with cigarette 
smoking, with a particular focus on tumor subgroups jointly classified according to the degree of 
invasiveness and histology. The study established that, the incidence of both borderline and 
invasive mucinous ovarian tumors increased among women with a history of cigarette smoking 
(OR 1.8, 95% CIs = 1.2–2.9, and OR 1.8, 95% C.I. = 0.8–4.3, respectively). Increased smoking 
duration and pack-years of exposure among women increased the risk of having these tumor 
types especially among women who had smoked within the previous 15 years. Overall, smoking 
was associated with a 30% increase in risk of epithelial ovarian cancer. In this study, 
demographic and lifestyle characteristics, family history of cancer, and reproductive history were 
obtained through in-person interviews spanning the period of time before diagnosis (for cases) or 
before an assigned, comparable reference date (for controls). Smoking history was initiated by 
questions on whether a woman had smoked a total of 100 or more cigarettes; if she had, 
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information on age at starting to smoke, and, if not smoking at the reference date, age at 
stopping. Women who had smoked also reported the total number of years smoked which 
accounts for time periods of non-smoking of at least one year’s duration as well as the typical 
number of cigarettes per day. Odds ratios (ORs) and 95% confidence intervals (CI) were 
calculated using unconditional logistic regression. The study adjusted for age (5-year intervals), 
county of residence (two strata), and year of diagnosis/reference date, number of full-term births, 
duration of hormonal contraception, education and other potential confounding factors. 
        Niwa Y. et al conducted a prospective study to examine the relation between cigarette 
smoking and the risk of ovarian cancer using data from the Japan Collaborative Cohort Study for 
Evaluation of Cancer Risk (Niwa 2005) from 1988 and found that cigarette smoking increases 
the risk of developing ovarian cancer in the Japanese population. 1990, 64 327 women from 45 
areas of Japan and aged 40–79 years registered based  on a basic health examination conducted 
under the Health and Medical Service Law for the Aged. Over an average of 7.6 years (range = 0 
– 10.0 years) which calculates as 266 366 person-years, a total of 39 women were diagnosed 
with ovarian cancer; fourteen cases with histologic diagnosis of serous carcinoma, four  cases of 
endometrial carcinoma, two cases of mucinous carcinoma, and nineteen cases with no detailed 
histologic diagnosis. Proportions of those who had never smoked and former and current 
smokers were 93.1% of the study population had never smoked, 1.6%, were former smokers and  
5.3% were current smokers. Cox proportional-hazards models were used to estimate relative 
risks (RR) and 95% confidence intervals (CI), adjusting for age at enrollment and study area; 
current smokers showed a significantly increased risk of ovarian cancer compared to those who 
had never smoked (RR = 2.63, 95% CI = 1.02–6.78).  In another multivariate analysis, RR were 
estimated adjusting for: body mass index, height, hormone replacement therapy, family history 
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of breast cancer and/or ovarian cancer, age at menarche, age at menopause, parity, alcohol 
consumption and education; current smokers were associated with an increased though not 
significant risk of ovarian cancer (RR = 2.27, 95% CI = 0.85–6.08) and former smokers were 
also non significantly positively associated with the risk of ovarian cancer. Relative risk was 
estimated for ovarian cancer for cigarettes per day, years smoked, and consumption in pack-
years among current smokers. Women who currently smoked 10–19 cigarettes per day had a 
significantly higher risk of developing ovarian cancer (RR = 3.50, 95% CI = 1.05–11.68) 
compared with those who had never smoked with risk also increased in women who were long-
term smokers at enrollment. Women who smoked 10–19 years were more than four times as 
likely as never smokers to develop ovarian cancer  (RR = 4.58, 95% CI = 1.07–19.59). 
Compared with those who had never smoked women who currently consumed 10–19 pack-years 
showed the highest relative risk (RR = 5.56, 95% CI =1.68–19.06). Women who smoked at least 
20 pack-years had an increased risk of ovarian cancer, but without statistical significance (RR = 
1.86, 95% CI = 0.25–14.30).  
        A meta-analysis of epidemiologic studies conducted to examine the association of 
endometrial cancer risk with cigarette smoking concluded that cigarette smoking is associated 
with lower risk of endometrial cancer, especially among postmenopausal women (Bo, Li et al. 
2008). The systematic literature search was limited to English-language articles up to June of 
2007 and was performed in MEDLINE and EMBASE to identify relevant studies. Out of the 220 
records identified from primary literature search, 48 articles were eventually selected as relevant 
for the study, but ten prospective and 24 case-control studies were included in the meta-analysis 
because six articles did not give risk estimates and 95% CIs, one publication was a duplicate of a 
previous report from the same study population and five articles did not adjust for any potential 
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risk factors. The included studies were conducted in United States (22), Canada (1), Europe (9) 
and Asia (2). Ever smoking was statistically significantly associated with a reduced risk of 
endometrial cancer among prospective studies (RR 0.81; 95% CI= 0.74-0.88) and case-control 
studies (OR 0.72; 95% CI=0.66-0.79). Pooled results of case-control studies found a statistically 
significant reduction in endometrial cancer risk for cigarette smoking among postmenopausal 
women (RR 0.71; 95% CI, 0.65-0.78) and not among premenopausal women (RR 1.06; 95% CI, 
0.88-1.28). The difference between two estimates was statistically significant (P =.01). One 
prospective study and five case-control studies which examined the association between cigarette 
smoking and risk of endometrial cancer according to HRT status showed that risk reduction 
appears be stronger among HRT users (RR 0.45; 95% CI, 0.29-0.70) than among nonusers (RR 
0.65; 95% CI, 0.51-0.84). An increase of 20 cigarettes smoked per day was significantly 
associated with 16% and 27% reduced risks of endometrial cancer in prospective and case-
control studies respectively; however, trends with increasing duration of smoking were not noted 
to allow confirmation of a linear increase in this association. 
        A health survey conducted from 1984–1986 among men and women aged 20 years and 
above in Nord-Trøndelag county in Norway (the HUNT Study) initially had 85,100 eligible 
persons. Lindeman et al followed 36, 761 women with a mean age of 49 years at baseline for an 
average of 15.7 years (range 0–19 years) to examine the relationship of body mass index (BMI), 
diabetes and smoking to endometrial cancer risk and found that women with known diabetes at 
baseline were three times as likely as women without diabetes to develop endometrial cancer 
(RR 3.13, 95% CI: 1.92–5.11); women who reported current smoking at baseline were at reduced 
risk compared to never smokers (RR 0.55, 95% CI: 0.35–0.86). The study concluded that, the 
strong linear positive association of BMI with endometrial cancer risk as well as a strongly 
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increased risk of endometrial cancer among women with diabetes could mean that any increase 
in body mass in the female population will increase endometrial cancer incidence  (Lindemann 
2008).  During follow-up, 222 endometrial cancers were diagnosed. Age-adjusted relative risks 
(RR) of BMI, diabetes and smoking with 95% confidence intervals was estimated using the Cox 
regression analysis whilst  mutually adjusting for each study factor including alcohol use, 
physical activity and hypertension. Analysis showed a strong and consistent increase in risk with 
increasing BMI (P-trend = 0.001); compared to women with BMI of 20–24 kgm_2, the age-
adjusted RR for BMI < 20 kgm_2 was 0.51 (95% CI: 0.19–1.40), and with BMI ≥ 40 kgm_2 was 
7.89 (95% CI: 3.90–15.94). After adjusting for diabetes, smoking status, alcohol use, physical 
activity and hypertension: adjusted RRs were: RR 6.36, 95% CI: 3.08–13.16; for BMI ≥ 40 
kgm_2; RR 4.28, 95% CI: 2.58–7.09 for BMI 35–39 kgm_2; and RR 0.53, 95% CI: 0.19–1.47 for 
BMI>20 kgm_2.  Among women with diabetes at baseline, 1.88% of the women were diagnosed 
with endometrial cancer during follow-up compared to 0.57% of women diagnosed with 
endometrial cancer without diabetes. After adjusting for confounders, diabetes was associated 
with a three-fold higher risk (RR 3.13, 95% CI: 1.92–5.11). Current smoking was inversely 
associated with endometrial cancer risk. After multivariable adjustment, a moderately reduced 
negative association with smoking was observed, RR 0.55, 95% CI: 0.35–0.86); for former 
smoking RR was 1.06, 95% CI: 0.71–1.61. 
 
 
 
 
 
Running Head: Breast and Gynecological Cancers                                                                                               26 
 
 
DATA AND METHODS 
NHANES data: 
        This study analyzes data from the National Health and Nutrition Examination survey 
(NHANES) which is a program of the National Centre for Health Statistics (NCHS) under the 
Centers for Disease Control and Prevention (CDC). NHANES is a continuous program of studies 
designed to combine the use of interviews and physical examinations to assess the health and 
nutritional status of children and adults in the United States; it examines a nationally 
representative sample of about 5,000 people a year located in counties across the country; 15 of 
which are visited each year. NHANES selects samples to represent U.S. population of all ages 
and oversamples people over 60 years as well as African Americans and Hispanics to ensure 
reliable statistics. NHANES conducts interviews using the Computer-Assisted Personal 
Interviewing-CAPI (interviewer administered) system. Persons aged 16 years and older and 
emancipated minors are interviewed directly. Interviews are done in respondents’ homes and 
examinations are done in mobile examination centers. 
         NHANES has collected information on a total of 52,195 people in living in the United 
States from the year 2001 to 2010 [n = 25,702 (49.2%) males and n = 26,293 (50.8%) females]. 
This study analyzes data from female respondents who are 20 years and above and gave valid 
response to the question of ever having been diagnosed with cancer or not (n = 14,300). All 
questions which were refused to be answered or answered as “don’t know” or had missing values 
are excluded from this study, apart from the question on smoking status. The sample size of the 
study is 6, 407. 
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Main Dependent and Independent variable: 
       The main dependent variable is breast cancer and gynecological cancer (GC). Gynecological 
cancer in this study comprises the three main GCs; cervical, ovarian and endometrial cancers. 
The two rare vaginal and vulvar cancers are excluded because information is not available on 
these variables from NHANES during the specified period of study. To obtain information on 
these variables, participants were asked “have you ever been told by a doctor or other health 
professional that you had cancer or a malignancy of any kind?” If the answer was yes, then the 
participant was asked “what kind of cancer was it?” All respondents who answered yes to breast, 
cervical, ovarian and uterine cancers are identified as cases in this study and randomly selected 
female respondents who said they had never been diagnosed with any kind of cancer or 
malignancy were classified as controls. 
Independent variables: 
        The main independent variables are cigarette smoking status and metabolic 
syndrome (MetS). Respondents are classified as current smokers if they answered yes to 
the question “have you smoked at least 100 cigarettes in life” and responded that they 
still smoke “every day” or “some days” as at the time of interview. Respondents who said 
they have not smoked up to 100 cigarettes in their life times are classified as non-
smokers. Metabolic syndrome is defined according to the guidelines of NCEP ATP III. 
Females who have at least three of the following conditions: a waist circumference of 
more than 88 cm, an average blood pressure of 130/85 mmHg or more, triglyceride level 
of 150 mg/dl or more, HDL-cholesterol level of less than 50 mg/dl, and a fasting glucose 
concentration of 100mg/dl or more. A third independent variable is concurrently having 
the metabolic syndrome and being a current smoker. 
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        Trained personnel take anthropometric measurements and study participants 
generally wear exam gowns otherwise a code is given to show that participants wore their 
own clothes; waist circumference is measured with measuring tape around the trunk in a 
horizontal plane of the midaxillary line of study participants in a standing position and 
holding their gowns up and at a minimal respiration to the nearest 0.1 cm. Certified BP 
examiners take the blood pressures of respondents/participants (R/P) in Mobile 
Examination Centers; after R/Ps have rested quietly in a sitting position for 5 minutes, the 
maximum inflation level (MIL) is determined and three consecutive blood pressure 
readings are obtained, a fourth reading may be taken if the BP measurement is interrupted 
or incomplete. The computer system is programmed by NHANES to capture; systolic 
blood pressure and maximum inflation level up to 300 mmHg, only even values of 
systolic and diastolic blood pressure and maximum inflation level, systolic blood pressure 
greater than diastolic blood pressure, a systolic blood pressure, only if there is diastolic 
blood pressure, and a diastolic blood pressure can be zero. In this study, average blood 
pressure is calculated by taking the average of the valid four blood pressure readings. In 
this study, average blood pressure is calculated by taking the average of the recorded 
blood pressure readings. Specimen collection for triglyceride levels, HDL-cholesterol 
levels, and fasting glucose concentrations are taken by trained NHANES laboratory staff 
at a mobile examination center. 
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Sample size and method of selection: 
         The total sample size for the study is 6407 females aged 20 years and above, who either 
have breast cancer, a gynecological cancer or said had not been diagnosed with a cancer and 
have valid values. From 2001 -2010, NHANES has records of 26,493 females and 14, 327 of 
them are aged 20 years and above. The study includes a total of 754 cases defined as 396 females 
who reported having breast cancer, 385 females who reported having a gynecological cancer; 
and 5653 randomly selected females who reported not having been diagnosed with any cancer. 
See diagram of selection criteria below. 
 
Statistical Analysis:  
        PASW statistics version 18.0 (SPSS Inc) was used to download data, merge and code for 
cases and controls. Initial descriptive analysis was run using SPSS to ensure that merging had 
been done correctly. SAS program version 9.2 was used to analyze data. The code proc freq and 
proc means was used to obtain the distribution of the continuous variables; sample size, mean, 
standard deviation and 95% confidence limits were estimated. Only percentages and sample size 
were calculated for other variables that were coded as categorical or dichotomous. Proc freq was 
also used to run bivariate analysis, chi square test statistics was estimated to compare the 
difference in proportion rates, p- value <.05 was considered a statistically significant relationship 
among variables. Odds ratios were also obtained for unadjusted rates. Proc logistic was used to 
run a logistic regression of relationships that had statistical significance under the proc freq 
bivariate analysis; breast and cervical cancer with different combinations of smoking and 
metabolic syndrome. Age, education, race marriage, country of birth and income to poverty ratio 
were entered as covariates for the analysis. Adjusted odds ratios and at 95% confidence limits 
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were estimated. Backward selection was done, to find the best model with the covariates 
however, the result obtained from this process either removed the independent variable of 
interest at an early stage or did not show much difference after removing certain variables, so the 
odds ratios estimated from the initial model are reported in this study. 
 
 
Figure 1: Diagram of selection process for females in the study 
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RESULTS 
Baseline Characteristics of Study Population 
        Demographics (Table 1A): The mean age of the 6407 selected females in this study is 60.2 
years (SD ± 14.16). The mean annual family income and annual household income of valid 
respondents in this study ranges between 25,000 US dollars to 45,000 US dollars; NHANES 
classifies annual family income and annual household income into 15 categories, with 1 being 
the least income ranging from 0 – 4,999 dollars and 15 being the highest income; as 100,000 and 
over. On the average, females in the study earn a middle income; the mean income to poverty 
ratio is 2.6 ± 1.6. At least 85% of the valid respondents said they had either emotional or 
financial support. The majority of the females; about 86% of the valid respondents are born in 
the United States and about 84% of valid respondents have lived in the United States for more 
than ten years. Nearly 87% of the valid respondents have some health insurance coverage. About 
70 % of the valid respondents have completed at least high school education. Nearly 61% of the 
study participants are non-Hispanic whites and about 50% of the valid respondents are married. 
See all of Table 1 for comparison of demographic characteristics between cases and control 
groups.  
        Examination and lifestyle: On the average, relevant females in the study population (Table 
1A) can be considered as having a normal diastolic blood pressure (< 85 mmHg; mean DBP, 60 
± 14) but high systolic blood pressure (> 130mmHg; mean SBP, 131 ± 22),  a normal plasma 
glucose level (< 110mg/dl, mean PGL, 109.8 ± 37.8 ), a good HDL-cholesterol level (> 50mg/dl; 
mean HDL, 58.8 ± 16.8), a normal triglyceride level of (< 150mg/dl; mean TG, 142.2 ± 107.2) 
but a high measure of central obesity (> 88cm; mean AO, 97.5 ±15.1) by the NCEP ATP III 
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standard. According to the classification of the National Heart Lung and Blood Institute (25.0 <= 
BMI <=29.9; mean BMI, 29.2 ± 6.9) and LCL-cholesterol in the near optimal/above optimal 
range (100 <= LDL<=129 mg/dl; mean LDL, 120.3 ± 36.9); females in this study are on the 
average, in the overweight group. The reported mean number of cigarettes smoked daily among 
VRs is about 17.0 ± 9.0 (Table 1C) and the mean cotinine level measured in the relevant study 
participants is 50.7 ± 124.0 (Table 1B). About 43% of the 6401 study participants have smoked 
at least 100 cigarettes in life (ever smokers) and 41% of them said they still smoke cigarettes; 
17.5% of the study participants are current smokers. About 15% of the valid respondents said 
they engage in work that involves at least ten minutes of vigorous activity like lifting heavy loads 
or climbing stairs daily, more than half of the VRs have had at least 12 alcoholic drinks /year in 
life and less than 40% of the VRs said they eat fewer high fat foods on their own. See table for 
comparison among cases and control groups. Overall, females in the control group seem to have 
better values for the risk factors listed. 
Medical Conditions and Reported Cancer Diagnosis among the Study Population 
        Breast and Gynecological cancers (Table 2A): Out of the 754 females in this study who 
reported having been diagnosed with breast cancer or a gynecological cancer, 396 (52.5%) of the 
BCEO is breast cancer, 194 (25.7%) of them being cervical cancer, 112 (14.9%) of them is 
endometrial cancer and 52 (6.9%) of them is ovarian cancer. On average, cervical cancer is 
diagnosed during the youngest age in this population; the mean age at first diagnosis of cervical 
cancer is 30.8 ± 11.6. Breast cancer is generally diagnosed at a later age among study 
participants; the mean age at first diagnosis of breast cancer is 58.1 ± 14.7. 
Metabolic syndrome and factors of metabolic syndrome (Table 2A): Almost 37% of the 
valid respondents have metabolic syndrome by the NCEP III standard. About; 28% of the 
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relevant females have a risky fasting plasma glucose level, 32% have a risky HDL cholesterol 
level, 34% have a risky triglyceride level, 47%  classified as having a risky blood pressure 
measurement and 72% have abdominal obesity. Out of 2884 relevant participants, 6.7% of them 
smoke and have the metabolic syndrome, 11.2% of them smoke only, 30.2% of them have 
metabolic syndrome only and 52.0% of them neither smoke nor have the metabolic syndrome 
(not shown in the tables) 
        Reproductive health (Table 2B):  Somewhere around 91% of valid respondents have been 
pregnant before, the average number of live births among VRs is three and almost 60% of VRs 
breastfed their children. Studies have associated age at menarche and menopause with BCEO. In 
this study, most (86.5%) of the VRs had their first menstrual period after age 15years and  61.6% 
of VRs had their last menstrual period at or after 45 years of age. About 61.1% of VRs have used 
birth control pills before and the majority (80.3%) of VRs has used hormone pills with estrogen 
only. The least hormone pill used is progestin only (17.5%) of valid respondents. About 25% of 
VRs have at least one ovary removed and nearly 38% of VRs have a hysterectomy even though 
comparatively, only about 12% of VRs had been diagnosed with endometriosis and about 21% 
with uterine fibroid. See all of Table 2 for comparison among case and control groups. 
Bivariate analysis  
        Smoking is highly significantly associated with breast and cervical cancer (p-value <.0001). 
Unadjusted results of bivariate analysis show that those who smoke are more likely to have been 
diagnosed with cervical cancer (OR 4.04; 95% CI, 3.02 – 5.40) than those who do not smoke. It 
seems that compared to those who do not smoke, those who smoke are less likely to have breast 
cancer (OR 0.58; 95% CI, 0.42 – 0.80).  The odds of having an endometrial or ovarian cancer 
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diagnosis among those who smoke compared to those who do not smoke is 1.06; 95% CI, 0.65 – 
1.72 and 1.02; 95% CI, 0.49 – 2.09 respectively (Table 3).  
        No statistically significant association is found between metabolic syndrome and breast 
cancer (p-value 0.42) or any of the gynecological cancers (p-value 0.44) in this study. Bivariate 
analysis shows no statistical significant association between having only one risk factor for 
metabolic syndrome, or having a combination of two or more risk factors of MetS and a BCEO 
cancer (Table 3). Observation from the population based study conducted by Antonio Russo et 
al. to describe the link between metabolic syndrome and cancer risk, also found a non-significant 
increased risk of breast and endometrial cancer among females. The association between BCEO 
and specific risk factors for metabolic syndrome was also considered (Table 4). Bivariate 
analysis shows that: a) fasting plasma glucose, HDL- cholesterol level and blood pressure are 
significantly associated with cervical cancer; p-value 0.012, <.0001 and <.0001 respectively, 
with increased odds of having cervical cancer associated with high levels of triglycerides and 
low levels of HDL cholesterol,  b) the existence of both hypertension and risky levels of plasma 
glucose are significantly associated with cervical cancer; p-value 0.029, c) fasting plasma 
glucose is significantly associated with endometrial cancer; p-value 0.046, d) a coexistence of 
hypertension and high HDL-cholesterol in a female, is associated with endometrial cancer; p-
value 0.036. In the Metabolic syndrome and cancer project (Me-Can) Borena et al observed 
significant increases in the relative risk for total cancer, as well as cervical cancers in the top 
quintile compared to the bottom quintile of serum triglycerides (Borena et al., 2011). 
        The association between smoking as well as metabolic syndrome and all the independent 
variables described above was also assessed. Bivariate analysis shows that: a) smoking is 
significantly associated with the following a) demographic variables: age, income to poverty 
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ratio, education, marital status and race; with average level of physical activity and b) medical 
conditions: abdominal obesity, HDL-cholesterol, blood pressure and a coexistence of high blood 
pressure and high blood glucose levels; and reproductive health factors like use of birth control 
pills, hysterectomy and HPV 18.  Metabolic syndrome is significantly associated with the 
following factors: age, income to poverty ratio, country of birth, education, race/ethnicity; 
average level of physical activity, alcohol use, perceived health condition, use of birth control 
pills, hysterectomy and having at least one ovary removed. The significant associations were 
determined for the purposes of identifying which variables to adjust for, in the regression model. 
        Distribution of BCEO by selected demographic variables (Table 5): The highest prevalence 
of reported cervical cancer diagnosis is observed in females between the ages of 30 – 39 years; 
as many as about 24% of VRs between the ages of 30 – 39 years reported having a cervical 
cancer diagnosis and only about eight percent of females in this group reported not having a 
cervical cancer diagnosis. The reverse is seen after age 70 years, only about nine percent of 
females in this age group reported having cervical cancer diagnosis whilst about 28% of females 
in this age group reported not having a diagnosis of cervical cancer. The percentage difference of 
females who reported diagnosis of breast cancer is highest among females after age 70 years; as 
much as about 54% of females who are 70 years and above reported a breast cancer diagnosis 
and only 30% did not report a breast cancer diagnosis in this age group (a difference of 24 
percentage point), whereas the percentage difference is less than ten among all the other age 
groups and carries a negative sign as well. About 14% of females between the ages of 20 -29 
years reported a cervical cancer diagnosis whereas about 0.2%, 6.2%, and 2.0% of females 
reported breast, endometrial and ovarian cancer respectively. 
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        Only about seven percent (p-value 0.012) of females with less than 9th grade level of 
education reported a diagnosis of cervical cancer and this percentage increases with level of 
education up to some college (32.5%) and drops to about 12% of females who are at least college 
graduates. Compared to females without a diagnosis of breast cancer, breast cancer diagnosis is 
4.2 percentage points less prevalent among females who are married, 5.0 percentage points less 
among females who are divorced, 0.9 percentage points less among separated, 2.7 percentage 
points less in never married females and 1.1 percentage points less in females who live with a 
partner, but as much as 14.1 percentage points more prevalent among widows (p-value <.001). 
Compared to females who do not have a diagnosis of cervical cancer, cervical cancer diagnosis is 
13.3 percentage points less prevalent among widows, 8.9 percentage points less prevalent among 
married females, 6.5 percentage points more prevalent among divorced females, 2 .0 percentage 
points more among females who are separated, 5.9 percentage points among never married 
females, and as much as 7.9 percentage points more among females who live with a partner (p-
value <0.001). 
        Cervical and endometrial cancers are statistically significantly related to poverty level; p-
value 0.0009 and 0.004 respectively. Cervical and endometrial cancers affect more females who 
live below the poverty level than females who live above the poverty level; the rates of reported 
diagnosis of these cancers decreases significantly with an increase in income (although for 
cervical cancer there seems to be a more decrease in rates of reports among middle income 
females than among high income females. Compared to those who do not have cervical cancer, 
females in low income, middle income and high income range are about 13.0 percentage points 
more, 6.9, and 6.1 percentage points less likely to be diagnosed with cervical cancer respectively. 
This pattern is observed in females who reported having a diagnosis for endometrial cancer; 
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compared to those who do not have endometrial cancer, females in low income, middle income 
and high income range are about 15.1 percentage points more, 4.8, and 10.3 percentage points 
less likely to be diagnosed with cervical cancer respectively. 
        Among the BCEO cancers, reported breast cancer diagnosis is significantly associated with 
race (p-value <.001). Non-Hispanic white and Non-Hispanic black females are more affected by 
breast cancer than females in other racial/ethnic groups; within racial groups, compared to those 
who do not have a breast cancer diagnosis, non-Hispanic whites are 11.0 percentage points more 
likely to have a breast cancer diagnosis and non-Hispanic blacks are about 1.0 percentage points 
more likely to have a breast cancer diagnosis.   Mexican Americans, other Hispanics, and 
females of other/Multiracial groups are less likely by 4.9, 2.5, and 2.6 percentage points to have 
a breast cancer diagnosis compared to females in the respective groups who do not have breast 
cancer (Table 5). 
        There is a significant association between the prevalence of cervical cancers and different 
combinations of females who smoke and have metabolic syndrome (p-value 0.0004), however no 
significant association was observed between the rates of the other cancers (breast, endometrial 
and ovarian) and different combinations of females who smoke and have metabolic syndrome (p-
value 0.104, 0.568, 0.818 respectively). Table 6C shows the rates of reported cancers among the 
different combinations of smoking and metabolic syndrome. Among those who smoke and do 
not have metabolic syndrome, the highest rates of reported BCEO cancer diagnoses was cervical 
cancer (32.5%), followed by ovarian cancer (11.1%), those who reported no cancer (10.9%), 
endometrial cancer (8.9%) and breast cancer (5.3%).  Among those who neither smoke nor have 
the metabolic syndrome, the highest rate of reported cancer diagnosis is ovarian cancer (61.1%) 
and the lowest is cervical cancer (34.9%). There are higher rates of cervical cancer diagnosis 
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among females who have the metabolic syndrome and smoke (13.3%), compared to endometrial 
cancer (8.9%), having no cancer (6.4%), ovarian cancer (5.6%) and breast cancer (5.3%) 
Consistent with findings in this study,  below 45 years of age: a) less females have breast 
cancer (4.6%) compared to females who do not (15.9%) and these females have a 75% less 
chance of reporting a breast cancer diagnosis than females above 45 years (OR 0.25; 95% CI 
3.51 – 6.71, p-value <.0001), b) more females have cervical cancer (49.9%) compared to females 
who do not (15.9%) and these females are almost five times as likely as females above 45 years 
to  report a cervical cancer diagnosis (OR 4.69; 95% CI 3.51 – 6.27, p-value <.0001) (Table 7).  
Females born in the United States are about two times as likely as females not born in the United 
States to report a breast cancer diagnosis (OR 2.12; 95% CI 1.26 – 3.57, p-value < 0.001).  
Females who have health insurance are four times as likely as females who do not have health 
insurance to report a breast cancer diagnosis (OR 4.05; 95% CI 2.4 -6.82, p-value < .001) and a 
47% less chance of reporting a cervical cancer diagnosis (OR 0.53; 95% CI 0.38 – 0.74, p-value 
< 0.001). This could be because females who do not have health insurance are economically 
challenged and since cervical cancer is more prevalent among females who are poor, it is follows   
that more females who do not have health insurance will report a cervical cancer diagnosis.       
Females in the low income group are 76 percent more likely than females in middle and high 
income groups to report a cervical cancer diagnosis (OR 1.76; 95% CI 1.30 -2.37, p-value < 
.001). Married females have a 30 percent less chance of reporting a cervical cancer diagnosis 
than females in the other marriage categories described (OR 0.70; 95% CI 0.52 – 0.93, p-value 
<.0001).Whites are 63 percent more likely to report a breast cancer diagnosis than females of 
other racial/ethnic groups (OR 1.63, 95% CI 1.30 – 2.04, p-value < 0.0001). Females who are 
current smokers have a 53 percent less chance of reporting a breast cancer diagnosis than 
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females above 45 years (OR 0.47; 95% CI 0.33 -0.68, p-value <.0001) and almost three times as 
likely as to have cervical cancer (OR 2.89; 95% CI 1.99 – 4.19, p-value <.0001). Females who 
are infected with the human papillomavirus 16 are almost four times as likely as uninfected 
females to have cervical cancer (OR 3.82; 95% CI 1.67 - 8.73, p-value <.001) and females 
infected with the human papillomavirus 18 are more than four times as likely as uninfected 
females to have cervical cancer (OR 4.35; 95% CI 1.23 -15.31, p-value <.05). 
        Females who have a high blood pressure have a 66 percent less chance of reporting a 
cervical cancer diagnosis than females who have a normal blood pressure (OR 0.44; 95% CI 0.31 
– 0.61, p-value <.0001).  Females who have a high fasting plasma glucose level have a 49 
percent less chance of reporting a cervical cancer diagnosis than females who have a normal 
fasting plasma glucose level (OR 0.51; 95% CI 0.29 – 0.87, p-value <.001). Females who have a 
high HDL-cholesterol levels are 65 percent more likely than females who have normal HDL-
cholesterol levels  to have cervical cancer (OR 1.65; 95% CI 1.22 – 2.23, p-value <.001)        
Logistic Regression analysis 
        Adjusting for age, education, race, marriage, country of birth and income to poverty ratio: 
females who have smoked more than hundred cigarettes in life and still smoke; a) have a 42 
percent less chance of having a breast cancer diagnosis than females who have smoked less than 
hundred cigarettes in life (OR 0.58; 95% CI 0.36 – 0.93, p-value 0.03), b) have a 2.67 increased 
odds of reporting a cervical cancer diagnosis than females who do not smoke (OR 2.67; 95% CI 
1.72 – 4.13, p-value <.0001) (Table 8A and 8B).  See all of Table 8 for the entire results of 
logistic regression analysis. 
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DISCUSSION 
        Family size was not taken into consideration so, the ratio of family income to poverty, was 
used as a more appropriate measure of income/poverty status. The cutoffs are based on the 
poverty guidelines recommended by the Department of Health and Human Services to categorize 
income to poverty ratio. Females having or living in a family with a ratio of income to poverty 
below 1.33 are classified as having a low income, from 1.33 to 3.22 as middle income and 
having more than 3.22 to 5.03 as having a high income, and above 5.03 as having a very high 
income. On the average, females in the study earned a middle income. There were no females in 
the very high income category. Because this study looks at patients diagnosed with cancer, 
having financial or emotional support was considered an important characteristic of the 
population because psychosocial problems can affect the diagnosis and treatment outcome of 
cancer (Easton 2010). At least 85% of the valid respondents said they had either emotional or 
financial support. This is a good indicator for health, well-being and success of treatment, 
especially when considering people afflicted by cancer. About 72% of the females in this study 
expressed that they had good to excellent health and nearly 87% of the valid respondents had 
some health insurance coverage.  Singer recommends that because emotional support is an 
important aspect of patient satisfaction, several members of the oncological team must provide it 
(Singer, Götze et al. 2009); this should actually include friends and family. Looking at the 
demographics, it can be said that the study participants are on the average of good socio-
economic status; averagely of middle income and at least 40% of the valid respondents have 
some college education and above. Because the mean age of the study population was 60.2 years, 
it was assumed that most of them had a higher possibility of having at least gone to college and 
the percentage cutoff for education was set for females in the study who had at least some 
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college education, however, less than half of the valid respondents had some education at college 
level or above, and about 70% of VRs had at least high school education. Zhu et al. explain that 
when assessing the relationship between smoking and education categorization is important 
because the relationship is not monotonic (Zhu, et al., 1996) and they list the recommended 
categories in years of education. The US Census Bureau reports that as at April 2010, non-
Hispanic whites made up about 64% of the US population (US Census Bureau, 2010) so the 
representation of non-Hispanic whites (61%) in this study is somehow representative of this.  
        NHANES measures cotinine levels to for purposes of measuring the prevalence and extent 
of tobacco use or of exposure to environmental tobacco smoke (ETS), and to describe their 
relationships with chronic health conditions, including respiratory and cardiovascular diseases. 
Cotinine is a major metabolite of nicotine that may be used as a marker for both active smoking, 
and as an index to Environmental Tobacco Smoke (ETS) exposure, or "passive smoking". 
Plasma cotinine has substantially longer half-life (15-20 hours) than nicotine (0.5–3 hours). 
Urine cotinine concentrations tend to be higher (3–8 times) in urine than in serum; however, for 
studies requiring a quantitative assessment of exposure, plasma or serum cotinine levels is 
preferred. The foundation for blood research considers cotinine levels <10 ng/mL to be 
consistent with no active smoking, 10 ng/mL to 100 ng/mL with light smoking or moderate 
passive exposure, and levels above 300 ng/mL with heavy smoking - more than 20 cigarettes a 
day. Because smoking status of the females in this study is based on self-reports, average 
cotinine levels by the three levels of smoking described above was calculated to check 
consistency with smoking status reports. The reported mean number of cigarettes smoked daily 
among VRs was about 17 ± 9 (Table 1C) and the mean cotinine level measured in the relevant 
study participants was 50.7 ± 124.1 (Table 1B). This level is quite consistent with the reports; 
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however it must be noted that out of the 1123 current smokers only 503 participants gave the 
number of cigarettes smoked daily whilst cotinine levels were measured in 5405 study 
participants. In this study, females who reported having smoked at least 100 cigarettes in life and 
still smoke were considered current smokers and those who have smoked less than 100 cigarettes 
in life including those who have possibly not smoked at all were considered nonsmokers. This is 
because in the questionnaire, NHANES asked only people who are under 20 years if they have 
ever smoked or not. This means that some people classified as non-smokers include never 
smokers and ever smokers who may actually have smoked at some time in their life, or may be 
still smoking if they are recent light smokers. The assumption for this study therefore, is that, 
smoking less than 100 cigarettes in life may not be enough of a contributory factor to a BCEO 
cancer. In this study, smoking is more prevalent among females who reported a cancer diagnosis 
than among those who have no cancer (See Table 1) 
        Non-Hispanic white and Non-Hispanic black females are more affected by breast cancer 
than females in other racial/ethnic groups. Non-Hispanic white females generally have a 
comparatively high incidence rate of breast cancer (Gomez, Quach et al. 2010) so this 
observation is not unusual. The association between race and breast cancer is quite difficult to 
explain because not only are the risk factors for breast cancer diverse; e.g. biologic factors, 
socioeconomic status, education, and cultural perspectives, but in this case, it could partly 
explained by the fact that more non-Hispanic whites have the means to screen for breast cancer 
(e.g. have health insurance) resulting in more of them reporting a breast cancer diagnosis if they 
should have one and therefore are predominantly reporting early or localized stage breast cancer 
(Sue, Mary et al. 2005); early detection rates of breast cancer is reported in literature among non-
Hispanic whites, (Summers, Saltzstein et al. 2010).  Non-Hispanics blacks are normally 
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diagnosed with advanced stages of breast cancer probably because of inability to screen earlier, 
but because this study does not look at the stages of cancer, it cannot be certain if the increase in 
breast cancer diagnosis observed in this group is mainly due to advanced breast cancer diagnosis 
(Lantz, Mujahid et al. 2006). However, The high cases of cervical cancer diagnosis among 
females who do not have health insurance compared to females who have health insurance could 
be because females who do not have health insurance are economically challenged and since 
cervical cancer is more prevalent among females who are poor, it follows that more females who 
do not have health insurance report a cervical cancer diagnosis, and this may actually be an 
advanced case of cervical cancer. 
        Results in this study also demonstrate that females born in the United States have a higher 
likelihood of having a breast cancer than females not born in the United States. The association 
between breast cancer diagnosis and females born in the United States needs further study. 
About 15% of the valid respondents said they engage in work that involves at least ten minutes 
of vigorous activity like lifting heavy loads or climbing stairs daily, more than half of VRs 
reported having had at least 12 alcoholic drinks /year in life and less than 40% of the VRs said 
they eat fewer high fat foods on their own. This information was included as an attempt to 
characterize the level of conscious effort made by the study participants to live a healthy life by 
engaging in physical activity , avoiding alcohol and fatty foods; indicators which have been 
proven to improve blood lipid levels resulting in good cardiovascular health, general well-being 
and a reduced risk for certain cancers. Msolly et al. found that physical activity can reduce breast 
cancer risk among certain age group (Msolly, Gharbi et al. 2011), Nicolas et al. observed that 
moderate to intense physical activity like heavy housework can help reduce the risk of breast 
cancer in some women (Nicolas, Adrien et al. 2011), Moore et al. also conclude that physical 
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activity reduces the risk of endometrial cancer (Moore, Gierach et al. 2010), Gudrun et al, 
describe several lifestyle activities including alcohol use, and diet as risk factors for 
gynecological cancers (Gudrun and Alison 2006). Drinking alcohol for example increases the 
level of endogenous estrogens, a known risk for breast cancer (Coronado, Beasley et al. 2011). 
Because no significant relationship was observed between the personal choice to eat fewer high 
fat foods, or some of the above mentioned variables and any of the cancers of interest in this 
study, the variables remain only as descriptive variables for the population.  
        The overall high prevalence of breast cancer diagnosis among females is consistent with 
literature. Breast cancer is the most common cancer diagnosed among women in the United 
States (SEER). It is likely that most females have either endometrial or ovarian cancers as a 
second gynecological cancer diagnosis; even though 112 females are listed as having 
endometrial cancer, 123 females gave the age at which endometrial cancer was diagnosed and 61 
females as against 52 females listed in the study gave the age at which ovarian cancer was 
diagnosed.  
Waist circumference above 88 cm is the most prevalent health risk factor in the study 
population. This is a very important observation because, increase in waist circumference 
(abdominal obesity) is a metabolic factor associated not only with the risk of several chronic 
diseases, especially cardiovascular diseases, but increased healthcare utilization and healthcare 
costs (Wolf, Finer et al. 2008). Okosun et al., found a significant increase in waist circumference 
and other factors of metabolic syndrome among American adolescents and recommend early 
lifestyle intervention to prevent the onset of cardiovascular diseases in adulthood (Okosun, Seale 
et al. 2012). About 37% of the relevant females were classified as having the metabolic 
syndrome in this study. Even though the use of diabetic medications to control blood glucose 
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levels was assessed; this including the use of medications prescribed to control risky or high 
levels of factors associated with metabolic syndrome were not considered in the study. This 
means that the number of females with metabolic syndrome in this study could be higher than 
stated, however another assumption made is that, if medications were being used appropriately, 
then it would manage the risky health factors and such females could qualify as having normal 
levels of these factors. 
        The use of birth control pills and hormones was assessed among the study participants. The 
least hormone pill used is progestin only; this is also consistent with the observation that females 
in the study are averagely in their mid-60’s and are not likely to use progestin only pills or even 
estrogen/progestin combination pills. Whereas the age at which these pills are used and for what 
purpose they are used is not a focus of this study, it is likely that because most of the females are 
in their mid-60’s the medication is used to manage postmenopausal symptoms. The percentage 
(about 25%) of VRs who have at least one ovary removed is not unusual for females in the 
United States; given the fact that technology is available for purposes of diagnosis, treatment or 
management of reproductive problems and several other conditions, and that about 
300,000 prophylactic oophorectomies (ovary removal) are performed annually in the United 
States (Parker, 2010). About 38% of VRs have had a hysterectomy even though comparatively, 
only about 12% of VRs have been diagnosed with endometriosis and about 21% with uterine 
fibroid before. Whereas there is a possibility that the diagnosis of an endometrial cancer may 
play a role in this, there may be other reasons which would be interesting to study. This 
information is also taken for descriptive purposes. Apart from the limitation posed by empty 
cells in running a regression with these variables, they were not adjusted for, because the study 
does not look at cancer incidence but cancer diagnosis at any point in life so correction rates for 
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ova removal or hysterectomy  (Merrill 2006) are assumed not to affect results of the study.  It 
must be noted that in this study, significant associations are observed between some reproductive 
health factors and BCEO which needs further study. 
Bivariate analysis showed no significant association at α = 0.05 between metabolic 
syndrome and gynecological cancers. Having metabolic syndrome seems to present a spurious 
relationship with BCEO cancer diagnosis. For example, even though some factors of metabolic 
syndrome are significantly associated with risk of cervical cancer, when they co-exist, the 
relationships between these variables change. From the findings, it is plausible that metabolic 
syndrome reduces the risk for example, breast cancer, but this is difficult to conclude because 
there may be other factors that contribute to this or confound this relationship, and this must be 
examined. One other observation is that significance changes when independent factors or 
certain combinations of factors of the metabolic syndrome are analyzed, as well as when certain 
cutoffs are used for categorization; for example whereas significance with age and BCEO is still 
consistent (p-value <.0001) after categorization, a significant association (p-value 0.012) which 
was not observed between education and cervical cancer and the significance between 
endometrial cancer and education (p-value 0.024) is not observed (p-value 0.342) after more 
levels of stratification is used (Table 5). A significant association is also observed between 
cervical cancer and hypertension or in combination with fasting plasma glucose. This could be a 
contributing factor to the absence of significance observed between metabolic syndrome and 
BCEO, because certain factors of the metabolic syndrome are significantly associated with some 
of the cancers of interest in this study. Metabolic syndrome is associated with several 
reproductive health factors (use of birth control pills, hysterectomy, ovary removal and probably 
more); this is an interesting area of research considering the observation that almost 40% of 
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females in this study have the metabolic syndrome and as much as 72% of women have 
abdominal obesity. 
        Far less females under 45 years reported having a diagnosis of breast cancer than cervical 
cancer (Figure 1). The highest prevalence of reported cervical cancer diagnosis is observed in 
females between the ages of 30 – 39 years and the least in females  aged 70 years and older 
however, the percentage of females with a diagnosis of breast cancer increases consistently with 
age. Two reasons for this could be because increased age is a breast cancer risk or that; females 
are living longer after a breast cancer diagnosis because of available treatment. Endometrial 
cancer also increases consistently with an increase in age but with a much narrower gap between 
those who report having a diagnosis of endometrial cancer and those who report no diagnosis of 
endometrial cancer. Ovarian cancer shows much the same pattern as endometrial cancer but the 
increase is not consistent with increase in age. Of all the BCEO, cervical cancer is a cancer that 
is more prevalent during young age.  
        Because the cases are reported cancer diagnosis, a report of no diagnosis should not be 
taken as absence of cancer diagnosis. Some females especially in the low income and low 
educated group may have undiagnosed cancer cases. Only about 7% (p-value 0.012) of females 
with less than 9th grade level of education reported a diagnosis of cervical cancer and this 
percentage increases with level of education up to some college (32.5%) and drops to about 12% 
of females who are at least college graduates. The finding among females with less than ninth 
grade is more likely to do with knowledge about screening services or inability to afford 
screening services, because less education could mean a less gainful employment and therefore 
less income. Smoking is another factor that is predominant among people with less than high 
school education; Zhu et al observed that the less than high school grade group consist of two 
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distinct categories when it comes to smoking, and that persons with 9 – 11 years of education 
tend to be current smokers compared to persons with 0 -8 years of education and recommend a 
categories for education when considering the relationship with smoking, (Zhu, Giovino et al. 
1996).  Accordingly, females with less than 9th grade level of education may be smoking less, 
thus resulting in the observed reduced cervical cancer diagnosis among in this group. 
        The observation of a high prevalence of breast cancer diagnosis among widows most likely 
has to do with the fact that the majority of widows are in the older age group around 70 years of 
age and therefore more consistent with results observed in the stratified age groups. By far less 
widows reported having cervical cancer compared to all other females in the other marriage 
categories and cervical cancer is also less among married females. The observation that more 
unmarried females among the other four marriage categories have cervical cancer, undoubtedly 
points to the fact that cervical cancer is a disease associated with sexual behavior; females who 
are unmarried and not widowed are more likely to have different sexual partners putting them at 
risk of infection with possibly HPV, eventually leading to cervical cancer diagnosis. Rothenberg 
explains this transmission dynamics by demonstrating that people who change their friends may 
change themselves and that quite unfortunately, it oftentimes results in an increased risk to a 
negative factor; that for example drug users who change their drug contact have more than three 
times the likelihood to be exposed to increased risk of any factor say, crime, or infection 
compared to baseline. (Rothenberg 2006). The high risk associated with HPV 16, 18 infection 
and cervical cancer (Silvia de, Wim et al. 2010) is demonstrated in results of this study (even 
though it is an unadjusted bivariate analysis).  Cervical and endometrial cancers affect more 
females who live below the poverty level than females who live above the poverty level. The 
high rate of reports of cervical cancer diagnosis among females in the low income group 
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indicates that cervical cancer is a problem of poverty. This is especially important because then, 
it is unlikely that females can afford to get screened for cervical cancer, detect precancerous 
changes early and have early treatment; an activity that is key to reducing the incidence and 
mortality due to cancer. Compared to cervical cancer, endometrial cancer hits females with low 
income more.  
        On the contrary, even though the differences in rates of reported diagnosis for breast and 
ovarian cancers across income to poverty ratios were not significant, breast cancer diagnosis 
seems to be less prevalent among females in the low income group than among females in 
middle and high income group, with less females in the low income group reporting a diagnosis 
of breast cancer compared to those who did not report a breast cancer diagnosis, and more people 
in the middle and high income group reporting a breast cancer diagnosis than those who did not. 
Reports of ovarian cancer diagnosis are however more prevalent among females in the low 
income group than females in the middle income group;  
        Smoking more than 30 cigarettes daily is consistently associated with an increase in cases of 
reported cancers compared to those who do not have these cancers. A paradoxical decrease in 
cases of reported endometrial cancers among females who smoke more than 30 cigarettes daily 
compared to absent cases of this cancer is observed. All these differences are however not 
significant for the specified categorization, all the p-values are above 0.05. 
       There is a significant association between cervical cancer and different combinations of 
females who smoke and have metabolic syndrome. Smoking is strongly associated with an 
increased probability of having cervical cancer, but a coexistence of metabolic syndrome and 
smoking seems to reduce the probability of having cervical cancer; this is an important 
observation which needs further study because some individual factors of the metabolic 
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syndrome (e.g increased triglycerides) are associated with increased odds of having some 
cancers including cervical cancer. In this study, no significant association was found between 
rates of diagnosis of the other cancers (breast, endometrial and ovarian) and different 
combinations of females who smoke and have metabolic syndrome, however certain factors like 
sample size and categorization may play a role in this, so further study is required. 
        The seemingly protective factor of smoking on breast cancer also needs further study, 
because research shows that smoking adversely affects almost all organ systems and nicotine has 
been shown to promote proliferation and metastatic properties of tumor cells. Several studies 
have found decreased odds of having breast cancer among those who smoke compared to those 
who do not smoke. Lesley Butler et al., explain that the apparent reduced risk of breast cancer 
among smokers is from the antiestrogenic but not the carcinogenic effects of smoking (Butler et 
al., 2010). The increased risk of breast cancer demonstrated among females under age 50 years 
who are BRCA1 and BRCA2 mutation carriers with a history of ever smoking, compared to 
never smokers (“Smoking and risk of breast cancer in carriers of mutations in BRCA1 or 
BRCA2 aged less than 50 years,” 2008) shows that smoking may actually not decrease the odds 
of breast cancer especially among breast cancer mutation carriers.  
        Figure 2 shows that during the midlife (50-59 years), breast and gynecological cancers are 
most likely to be diagnosed; females, who have not had any screening, should at least screen for 
breast and gynecological cancers at age 50 – 59 years. The strong significance found between 
hypertension and cervical cancer also requires further studies. The association between metabolic 
syndrome and reproductive indicators will be an important area of study in reproductive health. 
 
 
 
Running Head: Breast and Gynecological Cancers                                                                                               51 
 
STRENGTHS/LIMITATION 
        The strength of this study is the rigor with which NHANES collects data and the use of 
results from medical and laboratory examinations in certain cases. No self-reports were used in 
calculating metabolic syndrome among study participants. NHANES also collects rich 
information on the lifestyles and demographics of study participants and most of the variables 
relevant to this study are available from the NHANES data. Most studies looking at 
gynecological cancer were limited by the unavailability of such information. 
         One  limitation of this study is the use of self-reported cancer diagnosis; ideally 
information on cancer diagnosis from a cancer registry is preferred because it is more reliable 
and gives information on the types and severity or grades of cancer however; the consistency of 
results with findings in literature makes these self-reports quite reliable. 
One other limitation of this study is the inability to factor in time; the study looks at 
people who reported having been diagnosed with breast or a gynecological cancer from the year 
2001 to 2010 as well as their cigarette smoking status and factors of metabolic syndrome, 
however the length of exposure to risk factors and time of diagnosis is not accounted for. 
Even though there is rich information on reproductive health in the study participants, some 
important variables like use of birth control pills and other hormones, use of hypoglycemic or 
antihypertensive and hypolipemic medications were not controlled for, because the number of 
valid respondents did not match the regression model (empty cells) and no significance was 
observed in the bivariate analysis with some variables. It is also assumed that since adjusting for 
parity, year(s) of childbirth(s), and physical activity in the Norwegian cohorts, of the Me-Can 
study (Bjørge, Stocks et al. 2010) did not change the risk estimates by much, not adjusting for 
these in this study may also not change the odds ratios by much. It is must be noted that the total 
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number of females who gave the age at which BCEO was diagnosed are more than the total 
number of BCEO cancer cases in the study because some females reported having been 
diagnosed with more than one kind of cancer. NHANES allowed entry for up to three cancers, 
put respondents with more than four cancers in another category coded four different variables of 
cancer diagnosis in a year [MCQ230A, MCQ230B,MCQ230C,MCQ230D; (NHANES data)] but 
only MCQ230A which recorded the first kind of cancer reported was used in the analysis. One 
limitation that arises from this is that, the results of the analysis could be confounded by the 
existence of more than one kind of cancer in some females. This was not accounted for.  
 
CONCLUSION 
The rates of breast and gynecological cancers reported among females with the different 
combinations of smoking and metabolic syndrome do not follow a pattern consistent with 
increasing coexistence of these risk factors. Of the gynecological cancers, the rate of cervical 
cancer diagnosis is significantly higher among females, who only smoke, than among females 
who both smoke and have the metabolic syndrome; there were no statistically significant odds of 
increase or decrease in endometrial or ovarian cancer diagnosis among females with different 
combinations of smoking or metabolic syndrome. Smoking is statistically significantly 
associated with increased odds of having cervical cancer diagnosis. More females who have 
neither of the risk factors (smoke and metabolic syndrome) reported a diagnosis of breast cancer, 
than females who only have the metabolic syndrome or females who only smoke. Smoking is 
statistically significantly associated with decreased odds of having a breast cancer diagnosis. 
Running Head: Breast and Gynecological Cancers                                                                                               53 
 
Significantly, more females who live below the poverty line and females who are below 
the age of 45 years reported cervical cancer diagnosis and more white females reported breast a 
cancer diagnosis and more females who reported having breast cancer diagnosis have health 
insurance. Smoking and metabolic syndrome are very important indicators of reproductive health 
and needs further study. Because smoking is associated with increased odds of having cervical 
cancer, smoking cessation interventions should be an integral part of cervical cancer prevention 
programs and these programs should be targeted at younger females as well as females who live 
below the federal poverty level. 
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Table 1A: Distribution of Study Participants by Demographics, Examination and Lifestyle 
Characteristics 
    I. Demographics Sample size Mean ± SD 95% CL for mean 
Age 6407 60.2 ± 14.2 59.9 - 60.6 
Annual Family Income 3160 6.6 ± 3.2 6.5 - 6.8 
Annual Household Income 3046 6.8 ± 3.1 6.7 - 6.9 
Family PIR 5893 2.6 ± 1.6 2.6 - 2.7 
    
 
Sample size Yes, % 
 Anyone to help with emotional support 508 93.7 
 Anyone to help with financial support 502 85.7 
 Country of Birth(US) 3248 86.0 
 Covered by health insurance 6387 86.6 
 Education (high school and above) 6407 70.1 
 Length of time in US (5+ yrs.) 1097 93.0 
 Marital Status (Married) 6407 50.1 
 Race/ethnicity (Whites) 6407 60.7 
 
    
    II. Examination Sample size Mean ± SD 95% CL for mean 
Average diastolic blood pressure (mmHg) 6319 60 ± 14 68.7 - 69.4 
Average systolic blood pressure (mmHg) 6301 131 ± 22 130.6 -131.6 
Body Mass Index (kg/m-2) 6228 29.2 ± 6.9 29.1 - 29.4 
Cotinine (ng/mL) 5405 50.7± 124.0 47.4 – 54.0 
Glucose, plasma (mg/dL) 3080 109.8 ± 37.8 108.4 - 111.1 
HDL-cholesterol (mg/dL) 6297 58.8 ± 16.8 58.4 - 59.2 
LDL-cholesterol (mg/dL) 2983 120.3 ± 36.9 119.0 - 121.6 
Triglyceride (mg/dL) 3077 142.2 ± 107.2 138.4 -146.0 
Waist Circumference (cm) 6074 97.5 ±15.1 97.1 - 97.8 
    III. Lifestyle Sample size Mean ± SD 95% CL for mean 
Num. of cigarettes smoked per day now 503 16.8 ± 9.7 15.9 - 17.6 
    
 
Sample size Yes, % 
 Ave. level of PA daily (Stairs or heavy load) 3246 15.3 
 Eating fewer high fat foods on own 605 38.5 
 Had at least 12 alcohol drinks/1 yr.? 867 54.1 
 Smoked 100 cigarettes and still smoke 6406 17.5  
Smoked at least 100 cigarettes in life 6401 42.8 
 Take diabetic pills to lower blood sugar 635 58.0 
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Table 1B: Distribution of  Participants Who Reported a Breast or Gynecological Cancer Diagnosis 
(Cases) by Demographics, Examination and Lifestyle Characteristics 
 
I. Demographics Sample  size Mean ± SD 95% CL for mean 
Age 754 61.0±16.9 59.8 - 62.2 
Annual Family Income 393 6.3±3.4 6.0 - 6.7 
Annual Household Income 369 6.4±3.1 6.0 - 6.7 
Family PIR 679 2.5±1.6 2.4 - 2.6 
    
 
Sample size Yes, % 
 Anyone to help with emotional support 80 96.3 
 Anyone to help with financial support 80 88.8 
 Country of Birth(US) 403 90.8 
 Covered by health insurance 753 89.2 
 Education (high school and above) 754 70.7 
 Length of time in US (5+ yrs.) 90 93.3 
 Marital Status (Married) 754 46.0 
 Race/ethnicity (Whites) 754 65.8 
 
    
    II. Examination Sample size Mean ± SD 95% CL for mean 
Average diastolic blood pressure (mmHg) 666 67.7±14.6 66.6 - 68.8 
Average systolic blood pressure (mmHg) 648 130.0±21.6 128.3 - 131.6 
Body Mass Index (kg/m-2) 681 29.4±7.2 28.9 - 29.9 
Cotinine (ng/mL) 541 67.1±140.9 55.2 - 78.9 
Glucose, plasma (mg/dL) 331 109.2±36.0 105.3 - 113.1 
HDL-cholesterol (mg/dL) 644 57.5±16.9 56.1 - 58.8 
LDL-cholesterol (mg/dL) 306 116.9±37.0 112.8 - 121.1 
Triglyceride (mg/dL) 321 150.7±105.0 139.1 - 162.2 
Waist Circumference (cm) 649 98.0±16.0 96.7 - 99.2 
    III. Lifestyle Sample size Mean ± SD 95% CL for mean 
Num. of cigarettes smoked per day now 72 18.0 ± 9.3 15.8 - 20.2 
    
 
Sample size Yes, % 
 Ave. level of PA daily (Stairs or heavy load) 403 15.6 
 Eating fewer high fat foods on own 86 38.4 
 Had at least 12 alcohol drinks/1 yr.? 105 61.0 
 Smoked 100 cigarettes and still smoke  754 21.1 
 Smoked at least 100 cigarettes in life 754 50.3 
 Take diabetic pills to lower blood sugar 78 60.3 
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Table 1C: Distribution of  Participants Who Reported  No Cancer Diagnosis (Controls) by 
Demographics, Examination and Lifestyle Characteristics 
 
 I. Demographics Sample size Mean ± SD 95% CL for mean 
Age 5653 60.1±13.7 59.7 - 60.5 
Annual Family Income 2767 6.7±3.2 6.6 - 6.8 
Annual Household Income 2677 6.9±3.1 6.8 - 7.0 
Family PIR 5214 2.6±1.6 2.6 - 2.7 
    
 
Sample size Yes, % 
 Anyone to help with emotional support 428 93.2 
 Anyone to help with financial support 422 85.3 
 Country of Birth(US) 2845 85.3 
 Covered by health insurance 5634 86.2 
 Education (high school and above) 5653 70.1 
 Length of time in US (5+ yrs.) 1007 93.1 
 Marital Status (Married) 5653 50.7 
 Race/ethnicity (Whites) 5653 60.0 
 
    
    II. Examination Sample size Mean ± SD 95% CL for mean 
Average diastolic blood pressure (mmHg) 5653 69.2±14.3 68.8 - 69.6 
Average systolic blood pressure (mmHg) 5653 131.3±21.8 130.7 - 131.8 
Body Mass Index (kg/m-2) 5547 29.2±6.9 29.1 - 29.4 
Cotinine (ng/mL) 4864 48.9±121.9 45.4 - 52.3 
Glucose, plasma (mg/dL) 2749 109.8±38.0 108.4 - 111.2 
HDL-cholesterol (mg/dL) 5653 58.9±16.8 58.5 - 59.4 
LDL-cholesterol (mg/dL) 2677 120.7±36.9 119.3 - 122.1 
Triglyceride (mg/dL) 2756 141.2±107.5 137.2 - 145.2 
Waist Circumference (cm) 5425 97.4±15.0 97.0 - 97.8 
    III. Lifestyle Sample size Mean ± SD 95% CL for mean 
Num. of cigarettes smoked per day now 431 16.5±9.8 15.6 - 17.5 
    
 
Sample size Yes, % 
 Ave. level of PA daily (Stairs or heavy load) 2843 15.2 
 Eating fewer high fat foods on own 519 38.5 
 Had at least 12 alcohol drinks/1 yr.? 763 53.1 
 Smoked 100 cigarettes and still smoke  5652 17.1 
 Smoked at least 100 cigarettes in life 5647 41.8 
 Take diabetic pills to lower blood sugar 557 57.6 
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Table 2A: Distribution of Study Participants by Medical Conditions, Type of Reported Cancer and 
Reproductive Health Indicators 
    I. Medical condition Sample size Mean ± SD 95% CL for mean 
Age when breast cancer first diagnosed 397 58.1 ± 14.7 56.6 - 59.5 
Age when cervical cancer first diagnosed 196 30.8 ± 11.6 29.1 – 32.4 
Age when endometrial cancer first diagnosed 123 43.4 ±16.9 40.4 - 46.4 
Age when ovarian cancer first diagnosed 61 44.5 ± 16.1 40.3 - 48.6 
    
 
Sample size Yes % 
 Abdominal obesity 6074 71.7 
 Breast cancer  6049  6.6 
 Cervical cancer 5847  3.3 
 Endometrial cancer  5765  1.9 
 Ovarian cancer  5705 0.9 
 General health condition (good to excellent) 6403 71.9 
 Have cancer or not 6407 11.8 
 Metabolic syndrome 2885 36.7 
 Metabolic syndrome and smokes 2884 6.6 
 Risky fasting plasma glucose 3080 27.9 
 Risky HDL cholesterol level 6297 31.6 
 Risky triglyceride level 3077 33.6 
 Risky blood pressure  6179 47.3 
 
    
    II. Reproductive health Sample size Mean ± SD 
 No of pregnancies resulting in live births 1804 3.1 ± 2.1 3.0 - 3.2 
    
 
Sample size Yes % 
 Age range at first menstrual period(15+) 89 86.5 
 Age range at last menstrual period (45+) 258 61.6 
 Breastfed any of your children? 2655 57.6 
 Ever been pregnant? 866 91.2 
 Ever taken birth control pills? 5957 61.1 
 Had a hysterectomy 5421 37.9 
 Had at least 1ovary removed 3032 25.2 
 Told by doctor had endometriosis? 1070 11.6 
 Told by doctor had uterine fibroids? 1071 21.3 
 Use hormone pills w/estrogen only 1727 80.8 
 Used estrogen/progestin combo pills 1719 23.3 
 Used hormone pills w/progestin only 1712 17.5 
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Table 2B: Distribution of Study Participants who reported a Breast or Gynecological Cancer (Cases) by 
 Medical Conditions, Type of Reported Cancer and Reproductive Health Indicators 
 
I. Medical conditions Sample size Yes % 
Abdominal obesity 649 70.1 
Breast cancer  754 52.5 
Cervical cancer 754 25.7 
Endometrial cancer  754 14.9 
Ovarian cancer  754 6.9 
General health condition (good to excellent) 754 65.5 
Have cancer or not 754 100.0 
Metabolic syndrome 278 37.4 
Metabolic syndrome and smokes 278 8.3 
Risky fasting plasma glucose 331 28.1 
Risky HDL cholesterol level 644 35.4 
Risky triglyceride level 321 36.8 
Risky blood pressure  629 45.0 
 
  
   
   
   
   
II. Reproductive health Sample size Mean ± SD 
No of pregnancies resulting in live births 196 2.8 ± 1.8 
   
 
Sample size Yes % 
Age range at first menstrual period(15+) 12 0.0 
Age range at last menstrual period (45+) 28 57.1 
Breastfed any of your children? 289 59.5 
Ever been pregnant? 105 90.5 
Ever taken birth control pills? 643 59.3 
Had a hysterectomy 593 54.0 
Had at least 1ovary removed 331 38.1 
Told by doctor had endometriosis? 117 15.4 
Told by doctor had uterine fibroids? 115 25.2 
Use hormone pills w/estrogen only 200 80.0 
Used estrogen/progestin combo pills 195 21.0 
Used hormone pills w/progestin only 197 15.7 
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Table 2C: Distribution of Study Participants Who Reported  No Cancer (Controls) by 
 Medical Conditions, Type of Reported Cancer and Reproductive Health Indicators 
 
I. Medical Conditions Sample size Yes % 
Abdominal obesity 5425 71.8 
Breast cancer  0 0.0 
Cervical cancer 0 0.0 
Endometrial cancer  0 0.0 
Ovarian cancer  0 0.0 
General health condition (good to excellent) 5649 72.7 
Have cancer or not 754 0.0 
Metabolic syndrome 2607 36.7 
Metabolic syndrome and smokes 2606 6.4 
Risky fasting plasma glucose 2749 27.8 
Risky HDL cholesterol level 5653 31.1 
Risky triglyceride level 2756 33.3 
Risky blood pressure  5550 47.5 
    
 II. Reproductive health Sample size Mean ± SD 
No of pregnancies resulting in live births 1608 3.2 ± 2.1 
   
 
Sample size Yes % 
Age range at first menstrual period(15+) 77 15.6 
Age range at last menstrual period (45+) 230 62.2 
Breastfed any of your children? 2366 57.4 
Ever been pregnant? 761 91.3 
Ever taken birth control pills? 5310 61.3 
Had a hysterectomy 4828 35.9 
Had at least 1ovary removed 2701 23.6 
Told by doctor had endometriosis? 953 11.1 
Told by doctor had uterine fibroids? 956 20.8 
Use hormone pills w/estrogen only 1527 80.9 
Used estrogen/progestin combo pills 1524 24.3 
Used hormone pills w/progestin only 1515 17.8 
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Table 3: Bivariate Analysis Showing the Direct Unadjusted Effect of Smoking Status, Metabolic Syndrome  
and Factors of Metabolic Syndrome with Reported Breast and Gynecological Cancers 
 
 
Odds Ratio 95% CI 
P-value  
(Chi-square prob.) 
Current Smokers 
   Breast Cancer 0.58 0.42 - 0.80 < .001 
Cervical Cancer 4.04 3.02 - 5.40 < .0001 
Endometrial Cancer 1.06 0.65 - 1.72 0.82 
Ovarian Cancer 1.02 0.49 - 2.09 0.96 
    Metabolic Syndrome 
   Breast Cancer 1.16 0.81 - 1.66 0.42 
Cervical Cancer 0.83 0.52 - 1.33 0.44 
Endometrial Cancer 1.26 0.69 - 2.29 0.44 
Ovarian Cancer 0.66 0.24 - 1.87 0.44 
    One MetS Risk only 
   Breast Cancer 1.74 0.90 - 3.39 0.10 
Cervical Cancer 0.85 0.42 - 1.69 0.64 
Endometrial Cancer 1.13 0.38 - 3.34 0.82 
Ovarian Cancer 0.85 0.14 - 5.01 0.86 
    Two MetS Risk only 
   Breast Cancer 1.2 0.61 - 2.34 0.59 
Cervical Cancer 0.72 0.36 - 1.44 0.35 
Endometrial Cancer 1.06 0.36 - 3.08 0.91 
Ovarian Cancer 1.93 0.41 - 9.13 0.40 
    Three MetS Risk only 
   Breast Cancer 1.65 0.84 - 3.26 0.14 
Cervical Cancer 0.82 0.40 - 1.67 0.59 
Endometrial Cancer * 
  Ovarian Cancer * 
  
    Four MetS Risk only 
   Breast Cancer 1.63 0.77 - 3.45 0.19 
Cervical Cancer 0.39 0.14 - 1.09 0.06 
Endometrial Cancer 2.18 0.74 - 6.44 0.15 
Ovarian Cancer * 
  
    *some expected cell counts < 5 or unrealistically wide range of values; all five MetS risk have   
some expected cell counts < 5 so OR was not computed. 
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Table 4: Bivariate Analysis Showing Unadjusted Odds Ratios/ Significant Levels of Independent 
Variables of Interest with Reported Breast and Gynecological Cancers 
 
Demographics BC CC EC OC Smoke MetS 
Age < 45 years 0.25 4.69 1.22 1.59 2.28 0.39 
Family PIR 0.90 1.76 1.92 1.25 2.59 1.55 
Country of Birth(US) 2.12 2.07 1.07 0.73 2.77 0.75 
Education (high school and above) 1.12 1.23 0.74 0.63 0.83 0.49 
Length of time in US (5+ yrs.) 1.42 1.42 0.67 0.67 2.77 1.35 
Marital Status (Married) 0.84 0.70 1.04 0.83 0.60 0.79 
Race/ethnicity (Whites) 1.63 1.26 0.89 0.57 1.03 0.67 
Have health insurance 4.05 0.53 1.03 1.22 0.42 - 
 
 
 
      
Lifestyle BC CC EC OC Smoke MetS 
Ave level of PA daily (Stairs or heavy 
load) 0.91 1.58 0.67 0.93 1.25 0.64 
 
 
       
Medical condition BC CC EC OC Smoke MetS 
Abdominal obesity 0.89 0.99 0.76 1.29 0.70 - 
Risky fasting plasma glucose 1.24 0.51 1.76 0.72 0.83 - 
Risky HDL cholesterol level 1.02 1.65 1.24 1.1 1.75 - 
Risky triglyceride level 0.98 1.18 1.52 1.84 1.27 - 
Risky blood pressure  1.17 0.44 1.30 0.8 0.55 - 
 
 
       
Reproductive health BC CC EC OC Smoke MetS 
Ever taken birth control pills? 0.61 3.52 0.74 0.74 2.03 0.73 
HPV 16 2.39 3.82 - - 5.00 1.03 
HPV 18 2.14 4.34 - - 1.45 0.39 
 
 
 
significant at <.0001 level 
 
 
significant at <.001 level 
 
 
significant at <.05 level 
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Table 5: Proportions of Reported Breast and Gynecological Cancer Diagnosis compared to Reports 
of No Breast or Gynecological Diagnosis (NC) by Selected Demographic Variables and their Levels 
of Significance 
 
Age NC BC CC EC OC 
20-29yrs 0.2 0.3 13.9 6.2 1.9 
30-39yrs 8.1 1.8 23.7 8.0 13.5 
40-49yrs 15.8 7.6 21.7 9.8 15.4 
50-59yrs 22.3 12.4 20.6 12.5 11.5 
60-69yrs 25.7 24.9 10.8 27.7 32.7 
> 70yrs 53.5 53.5 9.3 25.7 25.0 
      Education NC BC CC EC OC 
< 9th grade 14.4 10.1 7.2 18.8 17.3 
9-11th grade 15.3 17.4 18.6 17.9 23.1 
High School grad/GED 25.4 25.0 29.4 26.8 26.9 
some college/AA  26.2 26.3 32.5 26.8 23.1 
<= college graduate  18.5 21.2 12.4 9.8 9.6 
      Marriage NC BC CC EC OC 
Married 50.7 46.5 41.8 51.8 46.2 
Widowed 21.0 35.1 7.7 21.4 23.1 
Divorced 15.1 10.1 21.6 11.6 15.4 
Separated 3.2 2.3 5.2 4.5 7.7 
Never married 7.0 4.3 12.9 5.4 3.8 
Live with Partner 2.9 1.8 10.8 5.4 3.8 
      PIR NC BC CC EC OC 
<1.33 29.9 27.6 42.9 45.0 34.8 
1.33 - < 3.22 33.8 35.0 26.9 29.0 28.3 
3.22 - < 5.03 36.3 37.3 30.2 26.0 37.0 
      Race/ethnicity NC BC CC EC OC 
Mexican American 12.7 7.8 10.3 15.2 19.2 
Other Hispanic 5.5 3.0 7.2 8.9 5.8 
Non-Hispanic White 60.0 71.0 65.5 57.1 46.2 
Non-Hispanic Black 16.8 17.8 12.9 15.2 25.0 
Other Race/Multiracial 5.1 2.5 4.1 3.6 3.8 
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Table 6A: Reported Breast and Gynecological Cancer Diagnosis Compared to Reports of No Breast 
or Gynecological Diagnosis by Number of Cigarettes Smoked Daily  
 
  
Breast Cancer (n= 18) No Cancer (n= 431) 
Number of cigarettes Sample size Percentage Percentage 
1-9 91 2.2 97.8 
10-19 142 3.5 96.5 
20-29 155 4.5 95.5 
30+ 61 6.6 93.4 
Total 449 4.0 96.0 
 
 
 
   
  
Cervical Cancer (n= 41) No Cancer (n= 431) 
Number of cigarettes Sample size Percentage Percentage 
1-9 93 4.3 95.7 
10-19 149 8.1 91.9 
20-29 169 12.4 87.6 
30+ 61 6.6 93.4 
Total 472 8.7 91.3 
 
 
 
   
  
Endometrial Cancer (n =10) No Cancer (n= 431) 
Number of cigarettes Sample size Percentage Percentage 
1-9 92 3.3 96.7 
10-19 140 2.1 97.9 
20-29 149 0.7 99.3 
30+ 60 5.0 95.0 
Total 441 2.3 97.7 
 
 
 
   
  
Ovarian Cancer ( n=3) No Cancer (n= 431) 
Number of cigarettes Sample size Percentage Percentage 
1-9 89 0.0 100.0 
10-19 138 0.7 99.3 
20-29 150 1.3 98.7 
30+ 57 0.0 100.0 
Total 434 0.7 99.3 
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Table 6B: Breast and Gynecological Cancer Diagnosis Compared to No Breast or Gynecological 
Diagnosis by Presence (+) or Absence (-) of Smoking and Metabolic Syndrome  
 
 
 
Breast Cancer (n= 132) No Cancer (n= 2606) 
Smoke &MetS Sample size Percentage Percentage 
 Smoke Mets (+ ; -) 291 2.4 97.6 
 Smoke Mets (- ; +) 835 5.5 95.5 
 Smoke Mets (+; +) 174 4.0 96.0 
 Smoke Mets (- ; -) 1438 5.0 95.0 
 Total 2738 4.8 95.2 
  
 
 
    
  
Cervical cancer (n= 83) No Cancer (n= 2606) 
Smoke &MetS Sample size Percentage Percentage 
 Smoke Mets (+ ; -) 311 8.7 91.3 
 Smoke Mets (- ; +) 805 2.0 98.0 
 Smoke Mets (+; +) 178 6.2 98.0 
 Smoke Mets (- ; -) 1395 2.1 97.9 
 Total 2689 3.1 96.9 
  
 
 
    
  
Endometrial cancer (n =45) No Cancer (n= 2606) 
Smoke &MetS Sample size Percentage Percentage 
 Smoke Mets (+ ; -) 288 1.4 98.6 
 Smoke Mets (- ; +) 804 1.9 98.1 
 Smoke Mets (+; +) 171 2.3 97.7 
 Smoke Mets (- ; -) 1388 1.6 98.4 
 Total 2651 1.7 98.3 
  
 
 
 
   
  
Ovarian cancer ( n=18) No Cancer (n= 2606) 
Smoke &MetS Sample size Percentage Percentage 
 Smoke Mets (+ ; -) 286 0.7 99.3 
 Smoke Mets (- ; +) 793 0.5 99.5 
 Smoke Mets (+; +) 168 0.6 99.4 
 Smoke Mets (- ; -) 1377 0.8 99.2 
 Total 2624 0.7 99.3 
  
See Notes on page 65 for explanation of (SmokeMetS combinations) 
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Table 6C: Rates  of Reported Breast and Gynecological Cancer Diagnosis  compared to Reports of 
No Breast or Gynecological Diagnosis ( NC) by Presence (+) or Absence (-) of Smoking and 
Metabolic Syndrome with their Levels of Significance 
 
Smoke & MetS NC BC CC EC OC 
Smoke Mets (+; -) 10.9 5.3 32.5 8.9 11.1 
Smoke Mets (-; +) 30.3 34.8 19.3 33.3 22.2 
Smoke Mets (+ ; +) 6.4 5.3 13.3 8.9 5.6 
Smoke Mets (- ; -) 52.4 54.6 34.9 48.9 61.1 
Total   100 100 100 100 100 
 
 
 
Note: 
• BC: Females who reported a breast cancer diagnosis 
• CC: Females who reported a cervical cancer diagnosis 
• EC: Females who reported an endometrial cancer diagnosis 
• OC: Females who reported an ovarian cancer diagnosis 
• NC: Females who reported no cancer diagnosis 
 
 
Note for Table 6B 
 
• Smoke (+) vs Smoke (-): Females who smoke compared to females who do not smoke 
• MetS (+) vs MetS (-): Females who have metabolic syndrome compared to females who do not 
have metabolic syndrome 
• Smoke /MetS (+ / +): Females who smoke and have metabolic syndrome 
• Smoke/ MetS (+ / -): Females who smoke and do not have metabolic syndrome. 
• Smoke /MetS (- / +): Females who do not smoke and have metabolic syndrome. 
• Smoke /MetS (- / -): Females who do not smoke and do not have metabolic syndrome. 
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Table 7A: Bivariate Analysis Showing Distribution of Reported Breast and Cervical Cancer 
Diagnosis (+) compared to No Cancer  Diagnosis Among Selected:  a)Confounding Variables 
and b) Main Independent Variables of Interest 
     
Demographics NC BC  OR; 95%CI CC  OR 
Age; < 45yrs 15.9 4.6 0.25(0.16-0.41) 46.9 4.69(3.51-6.27) 
      
Ave. PA; (Stairs, load) 15.2 14.1 0.91(0.61-1.36) 22.1 1.58(0.98-2.54) 
      
Country of Birth; US 85.3 92.5 2.12(1.26-3.57) 92.3 2.07(1.00-4.28) 
      
Educ.; > high school 70.7 72.5 1.12(0.90-1.41) 74.2 1.23(0.89-1.70) 
      
Health Insurance, Yes 86.2 96.2 4.05(2.40-6.82) 76.8 0.53(0.38-0.74) 
      
Marriage; Married 50.7 46.5 0.84(0.69-1.04) 41.8 0.70(0.52-0.93) 
      
PIR <1.33 29.9 27.6 0.90(0.70-1.14) 42.9 1.76(1.30-2.37) 
      
Race; Whites 60.0 71.0 1.63(1.30-2.04) 65.5 1.26(0.94-1.71) 
      
Time in US; 5years+ 93.0 95.0 1.42(0.34-6.00) 95.0 1.42(0.19-10.76) 
      HPV 16 1.5 3.5 2.40(0.72-7.92) 5.5 3.82(1.67-8.73) 
      
HPV 18 0.6 1.2 2.14(0.28-16.44) 2.4 4.34(1.23-15.31) 
 
 
      
Risk Factors NC BC OR; 95%CI CC OR 
Current Smoker 17.1 10.61 0.58(0.42-0.80) 45.4 4.04(3.02- 5.40) 
      
Metabolic Syndrome 36.7 40.2 1.16(0.81-1.66) 32.5 0.83(0.52-1.33) 
      
Hypertension 47.5 51.6 1.17(0.9-1.47) 28.3 0.44(0.31-0.61) 
      
HDL Cholesterol 31.1 31.5 1.02(0.80-1.29) 42.7 1.65(1.22-2.23) 
      
Fasting Glucose 27.8 32.3 1.23(0.89-1.74) 16.3 0.51(0.29-0.87) 
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Table 7B : Bivariate Analysis Showing Distribution of Reported Endometrial and Ovarian Cancer Diagnosis 
(+) compared to No Cancer  Diagnosis Among Selected:  a)Confounding Variables and b) Main Independent 
Variables of Interest 
 
Demographics NC EC OR; 95%CI OC OR; 95%CI 
Age; < 45yrs 15.9 18.8 1.22(0.76-1.97) 23.1 1.59(0.83-3.05) 
      Ave. PA; (Stairs, load) 15.2 10.8 0.67(0.30-1.48) 14.3 0.93(0.27-3.16) 
      Country of Birth; US 85.3 86.2 1.07(0.53-2.18) 81 0.73(0.24-2.19) 
      Educ.; > high school 70.7 63.4 0.74(0.50-1.09) 59.7 0.63(0.36-1.10) 
      Health Insurance, Yes 86.2 86.6 1.03(0.60-1.79) 88.5 1.22(0.52-2.88) 
      Marriage; Married 50.7 51.8 1.04(0.72-1.52) 46.2 0.83(0.48-1.44) 
      PIR <1.33 29.9 45.0 1.92(1.29-2.86) 34.8 1.25(0.68-2.30) 
      Race; Whites* 60.0 57.1 0.89(0.61-1.30) 46.2 0.57(0.33-0.99) 
      Time in US; 5years+ 93.0 90.0 0.67(0.15-2.96) 90 0.67(0.08-5.38) 
      HPV 16 1.5 0.0 - 0 - 
      HPV 18 0.6 0.0 - 0 - 
 
 
 
     Risk Factors NC EC OR; 95%CI OC OR; 95%CI 
Current Smoker 17.1 17.9 1.06(0.64-1.72) 17.3 1.02(0.49 - 2.09) 
  
    
Metabolic Syndrome 36.7 42.2 1.26(0.69-2.29) 27.8 0.66(0.24-1.87) 
      Hypertension 47.5 54.2 1.30(0.87-1.96) 42.1 0.80(0.42-1.53) 
      HDL Cholesterol 31.1 36.0 1.24(0.82-1.88) 33.3 1.11(0.59-2.06) 
      Fasting Glucose 27.8 40.4 1.76(1.00-3.08) 21.7 0.72(0.27-1.95) 
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Table 8A: Logistic Regression of Reported Breast Cancer Diagnosis with Main Independent Variables 
and Selected Factors of Metabolic Syndrome Adjusting for Age, Education, Race, Marriage, Country of 
Birth and Income to Poverty Ratio 
     
Risk Factors OR 95% CI p-value 
Pearson 
Goodness of fit 
Smoke (+) vs Smoke (-) 0.58 0.36 - 0.93 0.03 <0.01 
MetS (+) vs MetS (-) 0.82 0.49 - 1.39 0.46 0.77 
     
Smoke/MetS (+/+) vs Smoke/ MetS (-/-) 1.05 0.39 – 2.81 0.44 0.98 
Smoke/ MetS (+ / -)/ Smoke/ MetS (-/-) 0.51 0.18 - 1.48 0.30 
 Smoke /MetS (- / +)/ Smoke/ MetS (-/-) 0.70 0.40 – 1.25 0.67 
  
 
 
 
 
 
 
    Table 8B: Logistic Regression of Reported Cervical Cancer Diagnosis with Main Independent Variables 
and Selected Factors of Metabolic Syndrome Adjusting for Age, Education, Race, Marriage, Country of 
Birth and Income to Poverty Ratio 
 
     
Risk Factors OR 95% CI p-value 
Pearson 
Goodness-of-fit 
Smoke (+) vs Smoke (-) 2.67 1.72 – 4.13 <.0001 <0.0001 
MetS (+) vs MetS (-) 0.46 0.20 -1.10 0.08 0.13 
     
Smoke/MetS (+/+) vs Smoke/ MetS (-/-) 1.38 0.37-5.02 0.76 <0.0001 
Smoke/ MetS (+ / -) vs Smoke/ MetS (-/-) 3.03 1.41- 6.53 <0.01  
Smoke /MetS (- / +) vs Smoke/ MetS (-/-) 0.47 0.15 – 1.44* 0.03  
    
 
Hypertension 0.72 0.44 -1.21 0.22 0.01 
HDL Cholesterol 1.38 0.88 -2.16 0.16 0.01 
Fasting Glucose 0.51 0.20 -1.35 0.18 0.23 
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Table 8C: Logistic Regression of Reported Endometrial Cancer Diagnosis with Main Independent Variables 
and Selected Factors of Metabolic Syndrome Adjusting for Age, Education, Race, Marriage, Country of Birth 
and Income to Poverty Ratio 
 
 
 Risk Factors OR 95% CI p-value 
Pearson 
Goodness-of-fit 
Smoke (+) vs Smoke (-) 1.01 0.52 - 1.97 0.98 <.0001 
MetS (+) vs MetS (-) 1.16 0.48-2.76 0.74 0.02 
     
Smoke/MetS (+/+) vs Smoke/ MetS (-/-) 1.03 0.22 - 4.98 0.80 0.14 
Smoke/ MetS (+ / -) vs Smoke/ MetS (-/-) 0.57 0.12 - 2.67 0.45  
Smoke /MetS (- / +) vs Smoke/ MetS (-/-) 1.06 0.40 – 2.77 0.67  
 
 
 
 
 
Table 8D: Logistic Regression of Reported Ovarian Cancer Diagnosis with Main Independent Variables and 
Selected Factors of Metabolic Syndrome Adjusting for Age, Education, Race, Marriage, Country of Birth and 
Income to Poverty Ratio 
 
 
 Risk Factors OR 95% CI p-value 
Pearson 
Goodness-of-fit 
Smoke (+) vs Smoke (-) 0.90 0.25 - 3.18 0.86 0.09 
MetS (+) vs MetS (-) 0.23 0.03-1.96 0.18 0.44 
     
Smoke/MetS (+/+) vs Smoke/ MetS (-/-) - - - - 
Smoke/ MetS (+ / -) vs Smoke/ MetS (-/-) 0.98 0.11 - 8.66 0.96 <.0001 
Smoke /MetS (- / +) vs Smoke/ MetS (-/-) 0.27 0.03 - 2.30 0.97  
 
 
 
Note: 
ORs are not estimated when the maximum likelihood for  variables do not exist  
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Figure 1:  Rates of Reported Breast and Cervical Cancers by Socio-demographic Factors 
 
 
 
Figure 2: Rates of Reported Breast and Gynecological Cancers Stratified by Age. 
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SAS Code for Analysis 
LIBNAME BABSTHES ''; 
PROC IMPORT OUT= BABSTHES.MYTHESISBABS  
            DATAFILE= “THESIS\datatouse222.sav"  
            DBMS=SPSS REPLACE; 
RUN; 
 
DATA BABSTHES.NEWTHESIS; 
 SET BABSTHES.MYTHESISBABS; 
 
 IF SMOKES = 1 THEN NEWSMOKE = 1; 
 ELSE IF SMOKE NE . THEN NEWSMOKE = 2; 
  
 NAGE = .; 
 IF 20 <= AGE < 45 THEN NAGE = 1; 
 ELSE IF 45 <= AGE <= 85 THEN NAGE = 2; 
 
 IF AFI IN (77, 99) THEN AFI = .; 
 
 IF AHI IN (77, 99) THEN AHI = .; 
 
 IF EMOTIONALSUPP IN (7,9) THEN EMOTIONALSUPP = .; 
 
 IF FINANCIALSUPP IN (7,9) THEN FINANCIALSUPP = .; 
 
 IF HI IN (7,9) THEN HI = .; 
 
 IF EDUCATION IN (7,9) THEN EDUCATION = .; 
  
 NTIMEINUS = .; 
 IF TIMEINUS IN (77,99) THEN TIMEINUS = .; 
 IF 3 <= TIMEINUS <= 9 THEN NTIMEINUS = 1; 
 ELSE IF TIMEINUS IN (1,2) THEN NTIMEINUS = 2; 
 
 IF MARRIED IN (77,99) THEN MARRIED = .; 
 IF MARRIED = 1 THEN NMARRIED = 1; 
 ELSE NMARRIED = 2; 
 
 IF WTC IN (7,9) THEN WTC = .; 
 
 IF DIABPILLS IN (7,9) THEN DIABPILLS = .; 
 
 IF SMOKE IN (7,9) THEN SMOKE = .; 
 
 IF AGEBREAST IN (99999) THEN AGEBREAST = .; 
 
 IF AGECERV IN (99999) THEN AGECERV = .; 
 
 IF MENSRANGE IN (7,9) THEN MENSRANGE = .; 
 
 IF LASTRANGE IN (77,99) THEN LASTRANGE = .; 
 
 IF PREGNANT IN (7,9) THEN PREGNANT = .; 
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 IF CONTRACEP IN (7,9) THEN CONTRACEP = .; 
 
 IF HYSTERECTOMY IN (7,9) THEN HYSTERECTOMY = .; 
 
 IF OVAREMOVE IN (7,9) THEN OVAREMOVE = .; 
 
 IF ENDO IN (7,9) THEN ENDO = .; 
 
 IF FIBROID IN (7,9) THEN FIBROID = .; 
 
 IF OESTROGEN IN (7,9) THEN OESTROGEN = .; 
 
 IF OESTRPROG IN (7,9) THEN OESTRPROG = .; 
 
 IF PROGESTIN IN (7,9) THEN PROGESTIN = .; 
 
 IF 0 <= POVERTYINC < 1.33162 THEN MYPOV = 1; 
 ELSE IF POVERTYINC => 1.33162 THEN MYPOV = 2; 
 
 IF 0 <= POVERTYINC < 1.33162 THEN MYPOVNEW = 1; 
 ELSE IF 1.33162 <= POVERTYINC < 3.22046 THEN MYPOVNEW = 2; 
 ELSE IF 3.22046 <= POVERTYINC < 5.03326 THEN MYPOVNEW = 3; 
 ELSE IF POVERTYINC >= 5.03326 THEN MYPOVNEW =4; 
  
 IF  COUNTRYBORN = 1 THEN  NCOUNTRYBORN = 1; 
 ELSE  IF COUNTRYBORN >= 2 THEN  NCOUNTRYBORN = 2; 
 
 IF EDUCATION >= 3 THEN NEDUC = 1; 
 ELSE IF EDUCATION < 3 THEN NEDUC = 2; 
 
 IF RACE = 3 THEN NRACE = 1; 
 ELSE NRACE = 2; 
 
 IF AVEPA IN (3,4) THEN NAVEPA = 1; 
 ELSE IF AVEPA IN (1,2) THEN NAVEPA = 2; 
 
 IF BMI < 18.5 THEN NBMI = 1; 
 ELSE IF 18.5 <= BMI <= 24.9 THEN NBMI = 2; 
 ELSE IF 25 <= BMI <= 29.9 THEN NBMI = 3; 
 ELSE IF BMI >= 30 THEN NBMI = 4; 
 
 IF 1 <= NUMCIG <= 9 THEN NNUMCIG = 1; 
 ELSE IF 10 <= NUMCIG <= 19 THEN NNUMCIG = 2; 
 ELSE IF 20 <= NUMCIG <= 29 THEN NNUMCIG = 3; 
 ELSE IF NUMCIG >= 30 THEN NNUMCIG = 4; 
 
 NEWBREASTCANCER =  BREASTCANCER; 
 IF NEWBREASTCANCER = 2 THEN NEWBREASTCANCER = 0; 
 
 NEWCERVCANCER =  CERVCANCER; 
 IF NEWCERVCANCER = 2 THEN NEWCERVCANCER = 0; 
 
 NEWOVACANCER =  OVACANCER; 
 IF NEWOVACANCER = 2 THEN NEWOVACANCER = 0; 
 
 NEWUTERINECANCER =  UTERINECANCER; 
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 IF NEWUTERINECANCER = 2 THEN NEWUTERINECANCER = 0; 
  
 SMOKMETSYN = .; 
 IF NEWSMOKE = 1 AND METSYN = 1 THEN SMOKMETSYN = 1; 
 ELSE IF NEWSMOKE = 1 AND METSYN = 2 THEN SMOKMETSYN = 2; 
 ELSE IF NEWSMOKE = 2 AND METSYN = 1  THEN SMOKMETSYN = 3; 
 ELSE IF NEWSMOKE = 2 AND METSYN = 2  THEN SMOKMETSYN = 4; 
 
 NHHPV16 = .; 
 IF HHPV16 = 1 THEN NHHPV16 = 1; 
 ELSE IF HHPV16 = 2 THEN NHHPV16 = 2; 
 ELSE IF HHPV16 = 3 THEN NHHPV16 = 2; 
 ELSE IF OHPV16 = 1 THEN NHHPV16 = 1; 
 ELSE IF OHPV16 = 2 THEN NHHPV16 = 2; 
 ELSE IF OHPV16 = 3 THEN NHHPV16 = 2; 
 ELSE IF RHPV16 = 1 THEN NHHPV16 = 1; 
 ELSE IF RHPV16 = 2 THEN NHHPV16 = 2; 
 ELSE IF RHPV16 = 3 THEN NHHPV16 = 2; 
 
 NHHPV18 = .; 
 IF HHPV18 = 1 THEN NHHPV18 = 1; 
 ELSE IF HHPV18 = 2 THEN NHHPV18 = 2; 
 ELSE IF HHPV18 = 3 THEN NHHPV18 = 2; 
 ELSE IF OHPV18 = 1 THEN NHHPV18 = 1; 
 ELSE IF OHPV18 = 2 THEN NHHPV18 = 2; 
 ELSE IF OHPV18 = 3 THEN NHHPV18 = 2; 
 ELSE IF RHPV18 = 1 THEN NHHPV18 = 1; 
 ELSE IF RHPV18 = 2 THEN NHHPV18 = 2; 
 ELSE IF RHPV18 = 3 THEN NHHPV18 = 2; 
 
RUN; 
 
PROC CONTENTS DATA = BABSTHES.NEWTHESIS; 
RUN; 
 
ods html file ='THESIS\NEWALLDEMOFREQ.xls'; 
PROC MEANS DATA = BABSTHES.NEWTHESIS N MIN MAX MEAN STD CLM; 
 TITLE "MEANS, SD AND 95% CI OF DEMOGRAPHICS VARIABLES"; 
 VARS AGE AFI AHI POVERTYINC MYPOV; 
RUN; 
 
PROC FREQ DATA = BABSTHES.NEWTHESIS; 
 TITLE "DISTRIBUTION OF DEMOGRAPHICS VARIABLES"; 
 TABLES NAGE MYPOV EMOTIONALSUPP FINANCIALSUPP HI NEDUC NTIMEINUS 
NMARRIED RACE NCOUNTRYBORN; 
RUN; 
 
PROC MEANS DATA = BABSTHES.NEWTHESIS N MIN MAX MEAN STD CLM; 
 TITLE "MEANS, SD AND 95% CI OF EXAMINATION VARIABLES"; 
 VARS AVEDBP  AVESBP  BMI COTININE GLUCOSE HDL  LDLCHOL  HEIGHT TRIG WAISTCIR; 
RUN; 
 
PROC MEANS DATA = BABSTHES.NEWTHESIS N MIN MAX MEAN STD CLM; 
 TITLE "MEANS, SD AND 95% CI OF LIFESTYLE VARIABLES"; 
 VARS NUMCIG; 
RUN; 
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PROC FREQ DATA = BABSTHES.NEWTHESIS; 
 TITLE "DISTRIBUTION OF LIFESTYLE VARIABLES"; 
 TABLES AVEPA  WTC SMOKENOW  FATCONTROL  ALCOHOL  NEWSMOKE  DIABPILLS; 
RUN; 
 
PROC MEANS DATA = BABSTHES.NEWTHESIS N MIN MAX MEAN STD CLM; 
 TITLE "MEANS, SD AND 95% CI OF MEDICAL CONDITION VARIABLES"; 
 VARS AGEBREAST  AGECERV AGEOVARY  AGEUTERINE; 
RUN; 
 
PROC FREQ DATA = BABSTHES.NEWTHESIS; 
 TITLE "DISTRIBUTION OF MEDICAL CONDITION VARIABLES"; 
 TABLES ABDOBESITY BREASTCANCER CERVCANCER UTERINECANCER OVACANCER 
HCONDITON CANCER  METSYN SMOKMETSYN METSYNDROME 
           FASTGLUCOSE HDLCHOLEST  TRIGLYCERIDE HBP; 
RUN; 
 
PROC MEANS DATA = BABSTHES.NEWTHESIS N MIN MAX MEAN STD CLM; 
 TITLE "MEANS, SD AND 95% CI OF REPRODUCTIVE HEALTH VARIABLES"; 
 VARS LIVEBIRTHS; 
RUN; 
 
PROC FREQ DATA = BABSTHES.NEWTHESIS; 
 TITLE "DISTRIBUTION OF REPRODUCTIVE HEALTH VARIABLES"; 
 TABLES MENSRANGE  LASTRANGE  BREASTFED  PREGNANT  CONTRACEP 
HYSTERECTOMY OVAREMOVE  ENDO  FIBROID 
     OESTROGEN  OESTRPROG  PROGESTIN; 
RUN; 
 
ods html file ='THESIS\NEWYESCANCERFREQ.xls'; 
PROC MEANS DATA = BABSTHES.NEWTHESIS N MIN MAX MEAN STD CLM; 
 WHERE CANCER = 1;   
 TITLE "MEANS, SD AND 95% CI OF DEMOGRAPHICS VARIABLES YES CANCER"; 
 VARS AGE AFI AHI POVERTYINC MYPOV; 
RUN; 
 
PROC FREQ DATA = BABSTHES.NEWTHESIS; 
 WHERE CANCER = 1;  
 TITLE "DISTRIBUTION OF DEMOGRAPHICS VARIABLES YES CANCER"; 
 TABLES NAGE MYPOV EMOTIONALSUPP FINANCIALSUPP HI NEDUC NTIMEINUS 
NMARRIED RACE NCOUNTRYBORN; 
RUN; 
 
PROC MEANS DATA = BABSTHES.NEWTHESIS N MIN MAX MEAN STD CLM; 
 WHERE CANCER = 1;  
 TITLE "MEANS, SD AND 95% CI OF EXAMINATION VARIABLES YES CANCER"; 
 VARS AVEDBP  AVESBP  BMI COTININE GLUCOSE HDL  LDLCHOL  HEIGHT TRIG WAISTCIR; 
RUN; 
 
PROC MEANS DATA = BABSTHES.NEWTHESIS N MIN MAX MEAN STD CLM; 
 WHERE CANCER = 1;  
 TITLE "MEANS, SD AND 95% CI OF LIFESTYLE VARIABLES YES CANCER"; 
 VARS NUMCIG; 
RUN; 
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PROC FREQ DATA = BABSTHES.NEWTHESIS; 
 WHERE CANCER = 1;  
 TITLE "DISTRIBUTION OF LIFESTYLE VARIABLES YES CANCER"; 
 TABLES AVEPA  WTC SMOKENOW  FATCONTROL  ALCOHOL  NEWSMOKE  DIABPILLS; 
RUN; 
 
PROC MEANS DATA = BABSTHES.NEWTHESIS N MIN MAX MEAN STD CLM; 
 WHERE CANCER = 1;  
 TITLE "MEANS, SD AND 95% CI OF MEDICAL CONDITION VARIABLES YES CANCER"; 
 VARS AGEBREAST  AGECERV AGEOVARY  AGEUTERINE; 
RUN; 
 
PROC FREQ DATA = BABSTHES.NEWTHESIS; 
 WHERE CANCER = 1;  
 TITLE "DISTRIBUTION OF MEDICAL CONDITION VARIABLES YES CANCER"; 
 TABLES ABDOBESITY BREASTCANCER CERVCANCER UTERINECANCER OVACANCER 
HCONDITON METSYN SMOKMETSYN METSYNDROME 
           FASTGLUCOSE HDLCHOLEST  TRIGLYCERIDE HBP; 
RUN; 
 
PROC MEANS DATA = BABSTHES.NEWTHESIS N MIN MAX MEAN STD CLM; 
 WHERE CANCER = 1;  
 TITLE "MEANS, SD AND 95% CI OF REPRODUCTIVE HEALTH VARIABLES YES CANCER"; 
 VARS LIVEBIRTHS; 
RUN; 
 
PROC FREQ DATA = BABSTHES.NEWTHESIS; 
 WHERE CANCER = 1;  
 TITLE "DISTRIBUTION OF REPRODUCTIVE HEALTH VARIABLES YES CANCER"; 
 TABLES MENSRANGE  LASTRANGE  BREASTFED  PREGNANT  CONTRACEP 
HYSTERECTOMY OVAREMOVE  ENDO  FIBROID 
     OESTROGEN  OESTRPROG  PROGESTIN; 
RUN; 
 
ods html file ='THESIS\NEWNOCANCERFREQ.xls'; 
PROC MEANS DATA = BABSTHES.NEWTHESIS N MIN MAX MEAN STD CLM; 
 WHERE CANCER = 2;   
 TITLE "MEANS, SD AND 95% CI OF DEMOGRAPHICS VARIABLES NO CANCER"; 
 VARS AGE AFI AHI POVERTYINC MYPOV; 
RUN; 
 
PROC FREQ DATA = BABSTHES.NEWTHESIS; 
 WHERE CANCER = 2;  
 TITLE "DISTRIBUTION OF DEMOGRAPHICS VARIABLES NO CANCER"; 
 TABLES NAGE MYPOV EMOTIONALSUPP FINANCIALSUPP HI NEDUC NTIMEINUS 
NMARRIED RACE NCOUNTRYBORN; 
RUN; 
 
PROC MEANS DATA = BABSTHES.NEWTHESIS N MIN MAX MEAN STD CLM; 
 WHERE CANCER = 2;  
 TITLE "MEANS, SD AND 95% CI OF EXAMINATION VARIABLES NO CANCER"; 
 VARS AVEDBP  AVESBP  BMI COTININE GLUCOSE HDL  LDLCHOL  HEIGHT TRIG WAISTCIR; 
RUN; 
 
PROC MEANS DATA = BABSTHES.NEWTHESIS N MIN MAX MEAN STD CLM; 
 WHERE CANCER = 2;  
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 TITLE "MEANS, SD AND 95% CI OF LIFESTYLE VARIABLES NO CANCER"; 
 VARS NUMCIG; 
RUN; 
 
PROC FREQ DATA = BABSTHES.NEWTHESIS; 
 WHERE CANCER = 2;  
 TITLE "DISTRIBUTION OF LIFESTYLE VARIABLES NO CANCER"; 
 TABLES AVEPA  WTC SMOKENOW  FATCONTROL  ALCOHOL  NEWSMOKE  DIABPILLS; 
RUN; 
 
PROC MEANS DATA = BABSTHES.NEWTHESIS N MIN MAX MEAN STD CLM; 
 WHERE CANCER = 2;  
 TITLE "MEANS, SD AND 95% CI OF MEDICAL CONDITION VARIABLES NO CANCER"; 
 VARS AGEBREAST  AGECERV AGEOVARY  AGEUTERINE; 
RUN; 
 
PROC FREQ DATA = BABSTHES.NEWTHESIS; 
 WHERE CANCER = 2;  
 TITLE "DISTRIBUTION OF MEDICAL CONDITION VARIABLES NO CANCER"; 
 TABLES ABDOBESITY BREASTCANCER CERVCANCER UTERINECANCER OVACANCER 
HCONDITON METSYN SMOKMETSYN METSYNDROME 
           FASTGLUCOSE HDLCHOLEST  TRIGLYCERIDE HBP; 
RUN; 
 
PROC MEANS DATA = BABSTHES.NEWTHESIS N MIN MAX MEAN STD CLM; 
 WHERE CANCER = 2;  
 TITLE "MEANS, SD AND 95% CI OF REPRODUCTIVE HEALTH VARIABLES NO CANCER"; 
 VARS LIVEBIRTHS; 
RUN; 
 
PROC FREQ DATA = BABSTHES.NEWTHESIS; 
 WHERE CANCER = 2;  
 TITLE "DISTRIBUTION OF REPRODUCTIVE HEALTH VARIABLES NO CANCER"; 
 TABLES MENSRANGE  LASTRANGE  BREASTFED  PREGNANT  CONTRACEP 
HYSTERECTOMY OVAREMOVE  ENDO  FIBROID 
     OESTROGEN  OESTRPROG  PROGESTIN; 
RUN; 
 
ods html file ='THESIS \NEWSMOKEBIVARIATE.xls'; 
PROC FREQ DATA = BABSTHES.NEWTHESIS; 
 TITLE "BIVARIATE ANALYSIS WITH NEWSMOKE(UNADJUSTED)"; 
 TABLES NEWSMOKE*(BREASTCANCER CERVCANCER UTERINECANCER 
OVACANCER)/ALL; 
RUN; 
 
ods html file ='THESIS \NEWNNUMCIGBIVARIATE.xls'; 
PROC FREQ DATA = BABSTHES.NEWTHESIS; 
 TITLE "BIVARIATE ANALYSIS WITH NNUMCIG(UNADJUSTED)"; 
 TABLES NNUMCIG*(BREASTCANCER CERVCANCER UTERINECANCER OVACANCER)/ALL; 
RUN; 
 
ods html file ='THESIS\NEWSMOKMETSYNBIVARIATE.xls'; 
PROC FREQ DATA = BABSTHES.NEWTHESIS; 
 TITLE "BIVARIATE ANALYSIS WITH SMOKMETSYN(UNADJUSTED)"; 
 TABLES SMOKMETSYN*(BREASTCANCER CERVCANCER UTERINECANCER 
OVACANCER)/ALL; 
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RUN; 
 
ods html file ='THESIS\ALLBIVARIATE.xls'; 
PROC FREQ DATA = BABSTHES.NEWTHESIS; 
 TITLE "BIVARIATE ANALYSIS FOR TABLE 4.(UNADJUSTED)"; 
 TABLES (BREASTCANCER CERVCANCER UTERINECANCER OVACANCER NEWSMOKE 
SMOKMETSYN)* 
(NAGE MYPOV NCOUNTRYBORN NEDUC NTIMEINUS NMARRIED RACE HI AVEPA ABDOBESITY 
HCONDITON FASTGLUCOSE HDLCHOLEST  TRIGLYCERIDE HBP CONTRACEP) /ALL; 
RUN; 
 
ods html file ='THESIS \ALLBIVARIATENHHPV16.xls'; 
PROC FREQ DATA = BABSTHES.NEWTHESIS; 
 TITLE "BIVARIATE ANALYSIS FOR TABLE 4 PART2(UNADJUSTED)"; 
 TABLES (BREASTCANCER CERVCANCER UTERINECANCER OVACANCER NEWSMOKE 
SMOKMETSYN)*(NHHPV16 NHHPV18) /ALL; 
RUN; 
 
ods html file ='THESIS\BIVARIATETAB6C.xls'; 
PROC FREQ DATA = BABSTHES.NEWTHESIS; 
 TITLE "BIVARIATE ANALYSIS FOR TABLE 4 PART2(UNADJUSTED)"; 
 TABLES (SMOKMETSYN)*(CANCER BREASTCANCER CERVCANCER UTERINECANCER 
OVACANCER NEWSMOKE) /ALL; 
RUN; 
 
/************LOGISTIC REGRESSION FOR ADJUSTED RESULTS***************/ 
 
/****** BREAST CANCER ****************/  
 
/**** NEWSMOKE ****/ 
ods html file ='THESIS\NEWBREASTCANCERNEWSMOKELOGIS.xls'; 
PROC LOGISTIC DATA = BABSTHES.NEWTHESIS DESCENDING; 
 TITLE "PREDICTING USING LOGISTICS REGRESSION BREAST CANCER 
NEWSMOKE(ADJUSTED)"; 
 CLASS NEWBREASTCANCER NAGE MYPOV NCOUNTRYBORN NEDUC NMARRIED NRACE 
NEWSMOKE; 
 MODEL NEWBREASTCANCER = NAGE MYPOV NCOUNTRYBORN NEDUC NMARRIED NRACE 
NEWSMOKE/   
    SCALE=NONE AGGREGATE LACKFIT CLPARM=WALD LACKFIT RISKLIMITS; 
RUN; 
QUIT; 
 
ods html file ='THESIS\NEWBREASTCANCERNNUMCIGLOGIS.xls'; 
PROC LOGISTIC DATA = BABSTHES.NEWTHESIS DESCENDING; 
 TITLE "PREDICTING USING LOGISTICS REGRESSION BREAST CANCER 
NNUMCIG(ADJUSTED)"; 
 CLASS NEWBREASTCANCER NAGE MYPOV NCOUNTRYBORN NEDUC NMARRIED NRACE 
NNUMCIG; 
 MODEL NEWBREASTCANCER = NAGE MYPOV NCOUNTRYBORN NEDUC NMARRIED NRACE 
NNUMCIG/   
    SCALE=NONE AGGREGATE LACKFIT CLPARM=WALD LACKFIT RISKLIMITS; 
RUN; 
QUIT; 
 
ods html file ='THESIS\NEWBREASTCANCERSMOKMETSYNLOGIS.xls'; 
PROC LOGISTIC DATA = BABSTHES.NEWTHESIS DESCENDING; 
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 TITLE "PREDICTING USING LOGISTICS REGRESSION BREAST CANCER 
SMOKMETSYN(ADJUSTED)"; 
 CLASS NEWBREASTCANCER NAGE MYPOV NCOUNTRYBORN NEDUC NMARRIED NRACE 
SMOKMETSYN; 
 MODEL NEWBREASTCANCER = NAGE MYPOV NCOUNTRYBORN NEDUC NMARRIED NRACE 
SMOKMETSYN/   
    SCALE=NONE AGGREGATE LACKFIT CLPARM=WALD LACKFIT RISKLIMITS; 
RUN; 
QUIT; 
 
/****** CERVICAL CANCER ****************/  
 
/**** NEWSMOKE ****/ 
ods html file ='THESIS\NEWCERVCANCERNEWSMOKELOGIS.xls'; 
PROC LOGISTIC DATA = BABSTHES.NEWTHESIS DESCENDING; 
 TITLE "PREDICTING USING LOGISTICS REGRESSION CERVICAL CANCER 
NEWSMOKE(ADJUSTED)"; 
 CLASS NEWCERVCANCER NAGE MYPOV NCOUNTRYBORN NEDUC NMARRIED NRACE 
NEWSMOKE; 
 MODEL NEWCERVCANCER = NAGE MYPOV NCOUNTRYBORN NEDUC NMARRIED NRACE 
NEWSMOKE/  
    SCALE=NONE AGGREGATE LACKFIT CLPARM=WALD LACKFIT RISKLIMITS; 
RUN; 
QUIT; 
 
ods html file ='THESIS\NEWCERVCANCERNNUMCIGLOGIS.xls'; 
PROC LOGISTIC DATA = BABSTHES.NEWTHESIS DESCENDING; 
 TITLE "PREDICTING USING LOGISTICS REGRESSION CERVICAL CANCER 
NNUMCIG(ADJUSTED)"; 
 CLASS NEWCERVCANCER NAGE MYPOV NCOUNTRYBORN NEDUC NMARRIED NRACE 
NNUMCIG; 
 MODEL NEWCERVCANCER = NAGE MYPOV NCOUNTRYBORN NEDUC NMARRIED NRACE 
NNUMCIG/  
    SCALE=NONE AGGREGATE LACKFIT CLPARM=WALD LACKFIT RISKLIMITS; 
RUN; 
QUIT; 
 
ods html file ='THESIS\NEWCERVCANCERSMOKMETSYNLOGIS.xls'; 
PROC LOGISTIC DATA = BABSTHES.NEWTHESIS DESCENDING; 
 TITLE "PREDICTING USING LOGISTICS REGRESSION CERVICAL CANCER 
SMOKMETSYN(ADJUSTED)"; 
 CLASS NEWCERVCANCER NAGE MYPOV NCOUNTRYBORN NEDUC NMARRIED NRACE 
SMOKMETSYN; 
 MODEL NEWCERVCANCER = NAGE MYPOV NCOUNTRYBORN NEDUC NMARRIED NRACE 
SMOKMETSYN/  
    SCALE=NONE AGGREGATE LACKFIT CLPARM=WALD LACKFIT RISKLIMITS; 
RUN; 
QUIT; 
 
 
/****** OVARIAN CANCER ****************/  
 
/**** NEWSMOKE ****/ 
ods html file ='THESIS\NEWOVACANCERNEWSMOKELOGIS.xls'; 
PROC LOGISTIC DATA = BABSTHES.NEWTHESIS DESCENDING; 
Running Head: Breast and Gynecological Cancers                                                                                               79 
 
 TITLE "PREDICTING USING LOGISTICS REGRESSION OVARIAN CANCER 
NEWSMOKE(ADJUSTED)"; 
 CLASS NEWOVACANCER NAGE MYPOV NCOUNTRYBORN NEDUC NMARRIED NRACE 
NEWSMOKE; 
 MODEL NEWOVACANCER = NAGE MYPOV NCOUNTRYBORN NEDUC NMARRIED NRACE 
NEWSMOKE/  
    SCALE=NONE AGGREGATE LACKFIT CLPARM=WALD LACKFIT RISKLIMITS; 
RUN; 
QUIT; 
 
ods html file ='THESIS\NEWOVACANCERNNUMCIGLOGIS.xls'; 
PROC LOGISTIC DATA = BABSTHES.NEWTHESIS DESCENDING; 
 TITLE "PREDICTING USING LOGISTICS REGRESSION OVARIAN CANCER 
NNUMCIG(ADJUSTED)"; 
 CLASS NEWOVACANCER NAGE MYPOV NCOUNTRYBORN NEDUC NMARRIED NRACE 
NNUMCIG; 
 MODEL NEWOVACANCER = NAGE MYPOV NCOUNTRYBORN NEDUC NMARRIED NRACE 
NNUMCIG/  
    SCALE=NONE AGGREGATE LACKFIT CLPARM=WALD LACKFIT RISKLIMITS; 
RUN; 
QUIT; 
 
ods html file ='THESIS\NEWOVACANCERSMOKMETSYNLOGIS.xls'; 
PROC LOGISTIC DATA = BABSTHES.NEWTHESIS DESCENDING; 
 TITLE "PREDICTING USING LOGISTICS REGRESSION OVARIAN CANCER 
SMOKMETSYN(ADJUSTED)"; 
 CLASS NEWOVACANCER NAGE MYPOV NCOUNTRYBORN NEDUC NMARRIED NRACE 
SMOKMETSYN; 
 MODEL NEWOVACANCER = NAGE MYPOV NCOUNTRYBORN NEDUC NMARRIED NRACE 
SMOKMETSYN/  
    SCALE=NONE AGGREGATE LACKFIT CLPARM=WALD LACKFIT RISKLIMITS; 
RUN; 
QUIT; 
 
 
/****** UTERINE CANCER ****************/  
 
/**** NEWSMOKE ****/ 
ods html file ='THESIS\NEWUTERINECANCERNEWSMOKELOGIS.xls'; 
PROC LOGISTIC DATA = BABSTHES.NEWTHESIS DESCENDING; 
 TITLE "PREDICTING USING LOGISTICS REGRESSION UTERINE CANCER 
NEWSMOKE(ADJUSTED)"; 
 CLASS NEWUTERINECANCER NAGE MYPOV NCOUNTRYBORN NEDUC NMARRIED NRACE 
NEWSMOKE; 
 MODEL NEWUTERINECANCER = NAGE MYPOV NCOUNTRYBORN NEDUC NMARRIED 
NRACE NEWSMOKE/  
    SCALE=NONE AGGREGATE LACKFIT CLPARM=WALD LACKFIT RISKLIMITS; 
RUN; 
QUIT; 
 
ods html file ='THESIS\NEWUTERINECANCERNNUMCIGLOGIS.xls'; 
PROC LOGISTIC DATA = BABSTHES.NEWTHESIS DESCENDING; 
 TITLE "PREDICTING USING LOGISTICS REGRESSION UTERINE CANCER 
NNUMCIG(ADJUSTED)"; 
 CLASS NEWUTERINECANCER NAGE MYPOV NCOUNTRYBORN NEDUC NMARRIED NRACE 
NNUMCIG; 
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 MODEL NEWUTERINECANCER = NAGE MYPOV NCOUNTRYBORN NEDUC NMARRIED 
NRACE NNUMCIG/  
    SCALE=NONE AGGREGATE LACKFIT CLPARM=WALD LACKFIT RISKLIMITS; 
RUN; 
QUIT; 
 
ods html file ='THESIS\NEWUTERINECANCERSMOKMETSYNLOGIS.xls'; 
PROC LOGISTIC DATA = BABSTHES.NEWTHESIS DESCENDING; 
 TITLE "PREDICTING USING LOGISTICS REGRESSION UTERINE CANCER 
SMOKMETSYN(ADJUSTED)"; 
 CLASS NEWUTERINECANCER NAGE MYPOV NCOUNTRYBORN NEDUC NMARRIED NRACE 
SMOKMETSYN; 
 MODEL NEWUTERINECANCER = NAGE MYPOV NCOUNTRYBORN NEDUC NMARRIED 
NRACE SMOKMETSYN/  
    SCALE=NONE AGGREGATE LACKFIT CLPARM=WALD LACKFIT RISKLIMITS; 
RUN; 
QUIT; 
ods html close; 
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